Thickened pyridazinone compounds as PRMT5 inhibitors

CN118946549APending Publication Date: 2024-11-12BEIJING EARTHWISE TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031321.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-16
Filing Date
2023-04-19
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing PRMT5 inhibitors inhibit PRMT5 activity indiscriminately, leading to toxic side effects such as thrombocytopenia and anemia, and it is difficult to distinguish MTAP-deficient tumor cells from normal cells, affecting the therapeutic effect.

Method used

Develop an MTA synergistic inhibitor targeting the PRMT5/MTA complex, which can selectively inhibit PRMT5 activity, reduce the impact on normal cells, and significantly inhibit PRMT5 activity in MTAP-deficient tumor cells.

Benefits of technology

This inhibitor significantly improves the inhibitory effect on MTAP-deficient tumor cells, while reducing the toxic side effects on normal cells, expanding the treatment window, and has potential clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946549A_ABST
    Figure CN118946549A_ABST
Patent Text Reader

Abstract

The invention provides a PRMT5 inhibitor as shown in a formula (I), or pharmaceutically acceptable salts, isotope variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates of the PRMT5 inhibitor, or pharmaceutically acceptable salts, isotope variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates of the PRMT5 inhibitor. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and an effect of the compound in prevention and treatment of cancers. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Fused pyridazinone compounds as PRMT5 inhibitors Technical Field

[0001] The present invention relates to a novel class of PRMT5 inhibitors, or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates, or solvates thereof. The present invention also relates to methods for preparing the compounds, pharmaceutical compositions comprising the compounds, and the effects of the compounds in preventing and treating PRMT5-mediated diseases, such as cancer. Background Art

[0002] Protein arginine methyltransferase 5 (PRMT5) belongs to the class II PRMTs and is a S-adenosylmethionine (SAM)-dependent methyltransferase primarily responsible for symmetrically transferring the SAM methyl group to the terminal guanidinium nitrogen atom of arginine residues in histones and other proteins. In vivo, PRMT5 forms a complex with MEP50 (methylosome protein 50) for substrate recognition and localization. This complex is also required for PRMT5's catalytic activity in methyltransferases on histone 2A and histone 4. PRMT5 is a universal transcriptional repressor that regulates gene transcription and protein modification. Furthermore, PRMT5 plays a crucial role in tumor cell proliferation, differentiation, and apoptosis, making it a promising target for cancer therapy. However, PRMT5 is also essential for normal cells. PRMT5 knockout and siRNA knockdown studies have shown that inhibiting PRMT5 activity in normal tissues can cause numerous toxic side effects, including thrombocytopenia, infertility, skeletal muscle loss, and cardiac hypertrophy.

[0003] In 2016, multiple independent research groups reported that MTAP-deficient tumor cells have increased reliance on PRMT5 activity. MTAP deficiency upregulates intracellular levels of MTA (methylthioadenosine), a natural PRMT5 inhibitor. Therefore, MTAP-deficient tumor cells have increased reliance on PRMT5 activity, offering the potential to target MTAP-null tumor cells, specifically the PRMT5 / MTA complex, while sparing MTAP-WT cells.

[0004] The mechanisms of action of PRMT5 inhibitors under investigation include SAM-competitive inhibitors, substrate-competitive inhibitors, dual SAM-substrate competitive inhibitors, and MTA-synergistic inhibitors. Non-MTA-synergistic PRMT5 inhibitors indiscriminately inhibit PRMT5 activity and have been found to cause dose-limiting side effects such as thrombocytopenia, anemia, and neutropenia. MTA-synergistic inhibitors target the PRMT5 / MTA complex and are expected to inhibit MTAP-deficient tumor cells while eliminating their effects on MTAP-WT cells, potentially improving the therapeutic window.

[0005] Therefore, the development of PRMT5 inhibitors targeting the PRMT5 / MTA complex will have important clinical application value, and there is a demand for such inhibitors in the field.

[0006] Summary of the Invention

[0007] The present invention uses the PRMT5 / MTA complex as a target and develops a new class of small molecule inhibitors that can be used to treat various cancers.

[0008] The compounds of the present invention target the PRMT5 / MTA complex and are MTA-synergistic PRMT5 inhibitors. They exhibit excellent PRMT5 / MTA inhibitory activity and significant selectivity for the PRMT5 / SAM complex. Furthermore, they possess favorable ADMET (absorption-distribution-metabolism-excretion-toxicity) properties.

[0009] In one aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof:

[0010] in:

[0011] Z1, Z2 and Z3 are independently selected from N, CD or CH, and at least one of them is N;

[0012] Ring A is phenyl or a 5-6 membered heteroaryl group;

[0013] R1 is selected from H, D, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents;

[0014] R2 is selected from H, D, -C 0-6 Alkylene-halogen, -C 0-6 Alkylene -CN, -C 0-6 Alkylene-OR a 、-C 0-6Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0015] m = 0, 1, 2, or 3;

[0016] Wherein R is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R on the same carbon atom form C=O, C=S, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; or two R on adjacent atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0017] R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, preferably H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, which is optionally substituted by one or more D, halogen, C 1-6 Alkyl or C 1-6 haloalkyl substitution;

[0018] R a 、R b and R c Independently selected from H, C1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group;

[0019] Among them, ring A, R1, R2, R, R', R a 、R b and R c Each group in may be optionally substituted by D up to full deuteration.

[0020] In another aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof:

[0021] in:

[0022] Z1, Z2 and Z3 are independently selected from N, CD or CH, and at least one of them is N;

[0023] Ring A is phenyl or a 5-6 membered heteroaryl group;

[0024] R1 is selected from H, D, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents;

[0025] R2 is selected from H, D, -C 0-6 Alkylene-halogen, -C 0-6 Alkylene -CN, -C 0-6 Alkylene-OR a 、-C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0026] m = 0, 1, 2, or 3;

[0027] Wherein R is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C1-6 or two R on the same carbon atom form C=O, C=S, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; or two R on adjacent atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0028] R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, preferably H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0029] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group;

[0030] Among them, ring A, R1, R2, R, R', R a 、R b and R c Each group in may be optionally substituted by D up to full deuteration.

[0031] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, and optionally a pharmaceutically acceptable excipient, such as a carrier, adjuvant or vehicle.

[0032] In another aspect, the present invention provides a pharmaceutical composition containing a compound of the present invention and a pharmaceutically acceptable excipient, which further contains other therapeutic agents, such as those selected from the following target drugs / cell activity modulators, including CDK4 / 6 inhibitors, MAT2A inhibitors, MAPK1 / MAPK3 inhibitors, Type I PRMT inhibitors, EGFR inhibitors, SHP2 inhibitors, pan-KRAS inhibitors, KRASG12C inhibitors, RAF inhibitors, MEK inhibitors, ERK inhibitors, Bcl-2 inhibitors, SOS1 inhibitors, PARP inhibitors, MALT1 inhibitors, MALT2 inhibitors, BTK inhibitors, PI3K inhibitors, AKT inhibitors, FGFR inhibitors, DNA methyltransferase (DNMT) inhibitors, EZH1 / 2 inhibitors, EZH2 inhibitors, Menin-MLL inhibitors, IDH1 inhibitors, IDH2 inhibitors, IDH1 / 2 inhibitors, chemotherapy drugs, radiotherapy, STING agonists or immune checkpoint inhibitors / modulators.

[0033] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable excipient, and further comprising another therapeutic agent.

[0034] In another aspect, the present invention provides use of the compound of the present invention in the preparation of a medicament for treating and / or preventing a PRMT5-mediated disease.

[0035] In another aspect, the present invention provides a method for treating and / or preventing a PRMT5-mediated disease in a subject, comprising administering to the subject a compound of the present invention or a pharmaceutical composition of the present invention.

[0036] In another aspect, the present invention provides a compound of the present invention or a pharmaceutical composition of the present invention for use in treating and / or preventing a PRMT5-mediated disease.

[0037] In a specific embodiment, the present invention is used to treat and / or prevent cancer. In another specific embodiment, the present invention is used to treat and / or prevent the following cancers: Heart: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyosarcoma, fibroma, lipoma, and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondroma, hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, hemangioma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor), Kaposi's sarcoma, leiomyomas, hemangiomas, lipomas, neurofibromas, fibromas), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), Genitourinary tract: Kidney (adenocarcinoma, Wilms' tumor, lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma), choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, lipoma); Liver: Hepatocellular carcinoma, bile duct carcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: Gallbladder carcinoma, ampullary carcinoma, bile duct carcinoma; Bone: osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma, chronic exostosis of bone (osteocartilaginous exostoses), benign enchondromas, chondroblastomas, fibrochondromas, osteoid osteomas, and giant cell tumors; nervous system: skull (osteomas, hemangiomas, granulomas, xanthomas, and osteitis deformans); meninges (meningiomas, meningiosarcomas, and gliomas); brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors (pinealomas), glioblastomas multiforme, oligodendrogliomas, schwannomas, retinoblastomas, and congenital tumors); spinal neurofibromas, meningiomas, gliomas, and sarcomas); gynecological: uterus (endometrial cancer (seroma) Fluid-forming cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonic rhabdomyosarcoma), fallopian tube (carcinoma); Hematology: blood (myeloid leukemia (acute and chronic), acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma);Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, nevus dysplasia, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and Adrenal gland: neuroblastoma; especially MTAP-associated cancers such as hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.

[0038] In another specific embodiment, the PRMT5-mediated disease of the present invention is selected from the following cancers: malignant peripheral nerve sheath tumor, mesothelioma, glioblastoma multiforme, pancreatic cancer, bile duct cancer, prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, bladder cancer, astrocytoma, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, thymoma, head and neck cancer, hepatocellular carcinoma, laryngeal cancer, squamous cell carcinoma of the lung, lung adenocarcinoma, oral cancer, ovarian cancer, kidney cancer and thyroid cancer and sarcoma.

[0039] In another specific embodiment, the PRMT5-mediated disease of the present invention is selected from MTAP-related cancers, such as hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer or head and neck cancer.

[0040] definition

[0041] Chemical definition

[0042] Definitions of specific functional groups and chemical terms are described in more detail below.

[0043] When a numerical range is listed, it is intended to include every value and sub-range within the stated range. For example, "C 1-6 "Alkyl" includes C1, C2, C3, C4, C5, C6, C 1-6 、C 1-5 、C 1-4 、C 1-3 、C 1-2 、C 2-6 、C 2-5 、C 2-4 、C 2-3 、C 3-6 、C 3-5 、C 3-4 、C 4-6 、C 4-5 and C 5-6 alkyl.

[0044] “C 1-6 "Alkyl" refers to a straight or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms. In some embodiments, C 1-4 Alkyl and C 1-2 Alkyl groups are preferred. 1-6Examples of alkyl groups include: methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5), and n-hexyl (C6). The term “C 1-6 "Alkyl" also includes heteroalkyl groups in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkyl group may be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. Conventional alkyl abbreviations include: Me(-CH3), Et(-CH2CH3), iPr(-CH(CH3)2), nPr(-CH2CH2CH3), n-Bu(-CH2CH2CH2CH3), or i-Bu(-CH2CH(CH3)2).

[0045] “C 2-6 "Alkenyl" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. In some embodiments, C 2-4 Alkenyl is preferred. 2-6 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. The term "C 2-6 "Alkenyl" also includes heteroalkenyl groups in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). An alkenyl group may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0046] “C 2-6 "Alkynyl" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms, at least one carbon-carbon triple bond, and optionally one or more carbon-carbon double bonds. In some embodiments, C 2-4 Alkynyl is preferred. 2-6 Examples of alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), hexynyl (C6), and the like. The term "C 2-"Alkynyl" also includes heteroalkynyl groups in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkynyl group may be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0047] “C 1-6 "Alkylene" refers to the removal of C 1-6 In some embodiments, C 1-4 Alkylene, C 2-4 Alkylene and C 1-3 Alkylene is preferred. Unsubstituted alkylene includes, but is not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), hexylene (-CH2CH2CH2CH2CH2CH2-), and the like. Exemplary substituted alkylenes, for example, alkylenes substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted methylene (-CH(CH3)-, -C(CH3)2-), substituted ethylene (-CH(CH3)CH2-, -CH2CH(CH3)-, -C(CH3)2CH2-, -CH2C(CH3) 2- ), substituted propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CH2C(CH3)2-), and the like.

[0048] “C 0-6 "Alkylene" refers to the chemical bond and the above-mentioned "C 1-6 Alkylene", "C 0-4 "Alkylene" refers to the chemical bond and the above-mentioned "C 1-4 "Alkylene".

[0049] "Halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).

[0050] Therefore, “C 1-6 "Haloalkyl" refers to the above-mentioned "C 1-6 Alkyl", which is substituted by one or more halogen groups. In some embodiments, C 1-4 Halogenated alkyl is particularly preferred, more preferably C 1-2Haloalkyl. Exemplary haloalkyl groups include, but are not limited to, -CF3, -CH2F, -CHF2, -CHFCH2F, -CH2CHF2, -CF2CF3, -CCl3, -CH2Cl, -CHCl2, 2,2,2-trifluoro-1,1-dimethyl-ethyl, and the like. The haloalkyl group can be substituted at any available point of attachment, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0051] “C 3-10 "Cycloalkyl" refers to a non-aromatic cyclic hydrocarbon group having 3 to 10 ring carbon atoms and zero heteroatoms. In some embodiments, C 3-8 Cycloalkyl, C 3-7 Cycloalkyl and C 3-6 Cycloalkyl is particularly preferred, more preferably C 5-6 Cycloalkyl. Cycloalkyl also includes a ring system in which the above-mentioned cycloalkyl ring is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the cycloalkyl ring, and in such a case, the number of carbons continues to represent the number of carbons in the cycloalkyl system. Exemplary cycloalkyls include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), and the like. The cycloalkyl group may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0052] "3-12 membered heterocyclyl" refers to a saturated or unsaturated radical of a 3- to 12-membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon. In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as valence permits. In some embodiments, a 4-10 membered heterocyclyl is preferred, which is a 4 to 10 membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms; in some embodiments, a 3-8 membered heterocyclyl is preferred, which is a 3 to 8 membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms; a 4-8 membered heterocyclyl is preferred, which is a 4 to 8 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; a 4-7 membered heterocyclyl is preferred, which is a 4 to 7 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; a 4-6 membered heterocyclyl is preferred, which is a 4 to 6 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; and a 5-6 membered heterocyclyl is more preferred, which is a 5 to 6 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms. Heterocyclyl also includes a ring system in which the above-mentioned heterocyclyl ring is fused to one or more cycloalkyl groups, wherein the point of attachment is on the cycloalkyl ring, or a ring system in which the above-mentioned heterocyclyl ring is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring; and in such a case, the number of ring members continues to represent the number of ring members in the heterocyclyl ring system. Exemplary 3-membered heterocyclyls containing one heteroatom include, but are not limited to, aziridine, oxirane, and thiorenyl. Exemplary 4-membered heterocyclyls containing one heteroatom include, but are not limited to, azetidinyl, oxetane, and thiidine. Exemplary 5-membered heterocyclyls containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, pyrazolidinyl, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclic groups containing three heteroatoms include, but are not limited to, hexahydrotriazinyl. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thienyl.Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as 5,6-bicyclic heterocyclyl groups) include, but are not limited to, dihydroindolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinone, and the like. Exemplary 6-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as 6,6-bicyclic heterocyclyl groups) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like. Heterocyclyl groups also include those in which the above-mentioned heterocyclyl groups share one or two atoms with a cycloalkyl, heterocyclyl, aryl, or heteroaryl group to form a bridged or spirocyclic ring. The shared atoms may be carbon or nitrogen atoms, as valence permits. Heterocyclyl groups also include those in which the above-mentioned heterocyclyl and heterocyclyl groups may be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0053] “C 6-10 "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic) 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic arrangement) having 6-10 ring carbon atoms and zero heteroatoms. In some embodiments, an aryl group has six ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms ("C 10 Aryl also includes ring systems in which an aryl ring as described above is fused to one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the aryl ring, in which case the number of carbon atoms continues to refer to the number of carbon atoms in the aryl ring system. Aryl groups can be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0054] "5-14 membered heteroaryl" refers to a group of a 5-14 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic arrangement) having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as long as valence permits. Heteroaryl bicyclic ring systems may include one or more heteroatoms in one or both rings. Heteroaryl also includes ring systems in which the above-mentioned heteroaryl rings are fused to one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the heteroaryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the heteroaryl ring system. In some embodiments, 5-10 membered heteroaryl is preferred, which is a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms. In other embodiments, 5-6 membered heteroaryls are particularly preferred and are 5-6 membered monocyclic or bicyclic 4n+2 aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms. Exemplary 5-membered heteroaryls containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thienyl. Exemplary 5-membered heteroaryls containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryls containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl), and thiadiazolyl. Exemplary 5-membered heteroaryls containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryls containing one heteroatom include, but are not limited to, pyridinyl or pyridonyl. Exemplary 6-membered heteroaryls containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azacycloheptatrienyl, oxepinyl, and thieptatrienyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indanyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. A heteroaryl group can be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0055] The divalent groups formed by removing another hydrogen from the above-defined alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are collectively referred to as "subunits". The ring-forming groups such as cycloalkyl, heterocyclyl, aryl and heteroaryl groups are collectively referred to as "cyclyls".

[0056] Alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and the like are defined herein as optionally substituted groups.

[0057] Exemplary substituents on carbon atoms include, but are not limited to, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa 、-ON(R bb )2、-N(R bb )2、-N(R bb )3 + X - 、-N(OR cc )R bb 、-SH、-SR aa 、-SSR cc 、-C(=O)R aa 、-CO2H、-CHO、-C(OR cc )2, -CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2, -C(=O)NR bb SO2R aa 、-NRbb SO2R aa 、-SO2N(R bb )2, -SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3、-C(=S)N(R bb )2, -C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2R aa 、-P(=O)(R aa )2、-OP(=O)(R aa )2、-OP(=O)(OR cc )2、-P(=O)2N(R bb )2、-OP(=O)2N(R bb )2、-P(=O)(NR bb )2、-OP(=O)(NR bb )2、-NR bb P(=O)(OR cc )2、-NR bb P(=O)(NR bb )2、-P(R cc )2、-P(R cc )3、-OP(R cc )2、-OP(R cc )3、-B(R aa )2、-B(OR cc )2, -BR aa (OR cc ), alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0058] Or the two geminal hydrogen atoms on the carbon atom are replaced by groups =O, =S, =NN(R bb)2, =NNR bb C(=O)R aa 、=NNR bb C(=O)OR aa 、=NNR bb S(=O)2R aa 、=NR bb or = NOR cc replace;

[0059] R aa Each of R is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R aa The groups are combined to form a heterocyclyl or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0060] R bb Each of the following is independently selected from: hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc )2, -CO2R aa 、-SO2R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc )2, -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)2R aa 、-P(=O)(R aa )2、-P(=O)2N(R cc )2、-P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R bb The groups are combined to form a heterocyclyl or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0061] R ccEach of R is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R cc The groups are combined to form a heterocyclyl or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0062] R dd Each of the is independently selected from: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee 、-ON(R ff )2、-N(R ff )2,、-N(R ff )3 + X - 、-N(OR ee )R ff 、-SH、-SR ee 、-SSR ee 、-C(=O)R ee 、-CO2H、-CO2R ee 、-OC(=O)R ee 、-OCO2R ee 、-C(=O)N(R ff )2、-OC(=O)N(R ff )2、-NR ff C(=O)R ee 、-NR ff CO2R ee 、-NR ff C(=O)N(R ff )2、-C(=NR ff )OR ee 、-OC(=NR ff )R ee 、-OC(=NR ff )OR ee 、-C(=NR ff )N(R ff )2、-OC(=NR ff )N(R ff )2、-NR ff C(=NR ff )N(R ff )2、-NR ff SO2R ee 、-SO2N(R ff )2, -SO2R ee 、-SO2OR ee 、-OSO2R ee、-S(=O)R ee 、-Si(R ee )3、-OSi(R ee )3、-C(=S)N(R ff )2, -C(=O)SR ee 、-C(=S)SR ee 、-SC(=S)SR ee 、-P(=O)2R ee 、-P(=O)(R ee )2、-OP(=O)(R ee )2、-OP(=O)(OR ee )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg Group substitution, or two geminal R dd Substituents may combine to form =O or =S;

[0063] R ee Each of R is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R gg group substitution;

[0064] R ff Each of R is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R ff The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R gg group substitution;

[0065] R gg Each of the independently: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X - 、-NH(C 1-6 Alkyl)2 + X - 、-NH2(C 1-6 alkyl) + X - 、-NH3+ X - 、-N(OC 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 Alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 Alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 Alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 alkyl)2, -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1- 6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 Alkyl)2, -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 Alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6 Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 Alkyl), -SO2N(C 1-6 Alkyl)2, -SO2NH(C 1-6 alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 alkyl)3, -OSi(C 1-6 alkyl)3, -C(=S)N(C 1-6 alkyl)2、C(=S)NH(C 1-6alkyl), C(=S)NH2, -C(=O)S(C 1-6 alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)2(C 1-6 alkyl), -P(=O)(C 1- 6 alkyl) 2, -OP(=O)(C 1-6 alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C6-C 10 Aryl, C3-C7 heterocyclic, C5-C 10 heteroaryl; or two geminal R gg Substituents may combine to form =O or =S; wherein X - For the counter ion.

[0066] Exemplary substituents on nitrogen atoms include, but are not limited to, hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc )2, -CO2R aa 、-SO2R aa 、-C(=NR bb )R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc )2, -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)2R aa 、-P(=O)(R aa )2、-P(=O)2N(R cc )2, -P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R attached to the nitrogen atom ccThe groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd Group substituted, and wherein R aa 、R bb 、R cc and R dd As mentioned above.

[0067] Other definitions

[0068] The term "cancer" includes, but is not limited to, the following cancers: Heart: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyomas, fibromas, lipomas, and teratomas; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondroma, hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, hemangioma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor), Kaposi's sarcoma, leiomyomas, hemangiomas, lipomas, neurofibromas, fibromas), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Urogenital tract: Kidney (adenocarcinoma, Wilms' tumor, lymphoma, leukemia); Bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma); Prostate (adenocarcinoma, sarcoma); Testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma); Choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, lipoma); Liver: Hepatocellular carcinoma, bile duct carcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: Gallbladder carcinoma, ampullary carcinoma, bile duct carcinoma; Bone: osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma, chronic exostosis of bone (osteocartilaginous bone). exostoses), benign enchondromas, chondroblastomas, fibrochondromas, osteoid osteomas, and giant cell tumors; nervous system: skull (osteomas, hemangiomas, granulomas, xanthomas, and osteitis deformans); meninges (meningiomas, meningiosarcomas, and gliomas); brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors (pinealomas), glioblastomas multiforme, oligodendrogliomas, schwannomas, retinoblastomas, and congenital tumors); spinal neurofibromas, meningiomas, gliomas, and sarcomas); gynecological: uterus (endometrial cancer (seroma) Fluid-forming cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonic rhabdomyosarcoma), fallopian tube (carcinoma); Hematology: blood (myeloid leukemia (acute and chronic), acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma);Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, nevus dysplasia, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and Adrenal gland: neuroblastoma; especially MTAP-associated cancers such as hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.

[0069] In one embodiment, the term "cancer" includes, but is not limited to, the following cancers: malignant peripheral nerve sheath tumor, mesothelioma, glioblastoma multiforme, pancreatic cancer, bile duct cancer, prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, bladder cancer, astrocytoma, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, thymoma, head and neck cancer, hepatocellular carcinoma, laryngeal cancer, squamous cell carcinoma of the lung, adenocarcinoma of the lung, oral cancer, ovarian cancer, kidney cancer, and thyroid cancer, as well as sarcoma.

[0070] In one embodiment, the term "cancer" includes, but is not limited to, the following cancers: hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.

[0071] The term "treat" as used herein relates to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which the term applies, or one or more symptoms of such a disorder or condition. The noun "treat" as used herein relates to the action of the verb treat, which is as just defined.

[0072] As used herein, the term "pharmaceutically acceptable salt" refers to those carboxylate salts, amino acid addition salts of the compounds of the present invention that are suitable for use in contact with patient tissues within the scope of sound medical judgment, do not produce undue toxicity, irritation, allergic response, etc., are commensurate with a reasonable benefit / risk ratio, and are effective for their intended use, including (where possible) zwitterionic forms of the compounds of the present invention.

[0073] Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali metal and alkaline earth metal hydroxides or organic amines. Examples of metals used as cations include sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines include N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine.

[0074] Base addition salts of acidic compounds can be prepared by contacting the free acid form with a sufficient amount of the desired base in a conventional manner to form the salt. The free acid can be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner. The free acid forms differ somewhat from their respective salt forms in certain physical properties, such as solubility in polar solvents, but for the purposes of this invention, the salts are equivalent to their respective free acids.

[0075] Salts can be sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides prepared from inorganic acids such as hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, and the like. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, toluenesulfonate, citrate, maleate, fumarate, succinate, tartrate, naphthoate, methanesulfonate, glucoheptonate, lactobionate, laurylsulfonate, and isethionate, and the like. Salts can also be prepared from organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like. Representative salts include acetate, propionate, octanoate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, naphthoate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Pharmaceutically acceptable salts may include cations based on alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Salts of amino acids, such as arginate, gluconate, galacturonate, and the like are also contemplated (see, e.g., Berge SM et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977; 66: 1-19, incorporated herein by reference).

[0076] "Subjects" to be administered include, but are not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)) and / or non-human animals, e.g., mammals, e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. The terms "human," "patient," and "subject" are used interchangeably herein.

[0077] "Disease," "disorder," and "condition" are used interchangeably herein.

[0078] As used herein, and unless otherwise indicated, the term "treating" includes actions that occur while a subject has a particular disease, disorder, or condition that reduces the severity of, or delays or slows the development of, the disease, disorder, or condition ("therapeutic treatment"), as well as actions that occur before a subject develops a particular disease, disorder, or condition ("prophylactic treatment").

[0079] Generally, an "effective amount" of a compound is an amount sufficient to elicit the desired biological response. As will be appreciated by those skilled in the art, the effective amount of a compound of the invention can vary depending on factors such as the biological target, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and symptoms of the subject. An effective amount includes both a therapeutically effective amount and a prophylactically effective amount.

[0080] As used herein, and unless otherwise specified, a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more symptoms associated with the disease, disorder, or condition. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective amount" can include an amount that improves overall treatment, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic effects of other therapeutic agents.

[0081] As used herein, unless otherwise specified, a "prophylactically effective amount" of a compound is an amount sufficient to prevent a disease, disorder, or condition, or an amount sufficient to prevent one or more symptoms associated with a disease, disorder, or condition, or an amount to prevent the recurrence of a disease, disorder, or condition. A prophylactically effective amount of a compound refers to an amount of a therapeutic agent, alone or in combination with other agents, that provides a prophylactic benefit in preventing a disease, disorder, or condition. The term "prophylactically effective amount" can include an amount that improves overall prevention, or an amount that enhances the prophylactic effect of other prophylactic agents.

[0082] "Combination" and related terms refer to the simultaneous or sequential administration of a compound of the invention and other therapeutic agents. For example, a compound of the invention can be administered simultaneously or sequentially with the other therapeutic agents in separate unit dosage forms, or can be administered simultaneously with the other therapeutic agents in a single unit dosage form. BRIEF DESCRIPTION OF THE DRAWINGS

[0083] Figures 1 and 2 show the results of in vivo pharmacodynamic studies in the LU99 CDX model. Specific implementation plan

[0084] Herein, "compounds of the present invention" refer to the following compounds of formula (I), formula (II), etc. (including sub-general formulas, such as formula (I-1) to formula (IV-1), etc.), and pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates thereof.

[0085] Herein, compounds are named using standard nomenclature. For compounds with asymmetric centers, it should be understood that (unless otherwise specified) all optical isomers and mixtures thereof are encompassed. In addition, unless otherwise specified, all isomeric compounds encompassed by the present invention may occur in both Z and E forms with carbon-carbon double bonds. Compounds that exist in different tautomeric forms are not limited to any particular tautomer, but are intended to encompass all tautomeric forms.

[0086] In one embodiment, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof:

[0087] in:

[0088] Z1, Z2 and Z3 are independently selected from N, CD or CH, and at least one of them is N;

[0089] Ring A is phenyl or a 5-6 membered heteroaryl group;

[0090] R1 is selected from H, D, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents;

[0091] R2 is selected from H, D, -C 0-6 Alkylene-halogen, -C 0-6 Alkylene -CN, -C 0-6 Alkylene-OR a 、-C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0092] m = 0, 1, 2, or 3;

[0093] Wherein R is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6Alkyl or C 1-6 or two R on the same carbon atom form C=O, C=S, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; or two R on adjacent atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0094] R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, preferably H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, which is optionally substituted by one or more D, halogen, C 1-6 Alkyl or C 1-6 haloalkyl substitution;

[0095] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group;

[0096] Among them, ring A, R1, R2, R, R', R a 、Rb and R c Each group in may be optionally substituted by D up to full deuteration.

[0097] In another embodiment, the present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof:

[0098] in:

[0099] Z1, Z2 and Z3 are independently selected from N, CD or CH, and at least one of them is N;

[0100] Ring A is phenyl or a 5-6 membered heteroaryl group;

[0101] R1 is selected from H, D, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents;

[0102] R2 is selected from H, D, -C 0-6 Alkylene-halogen, -C 0-6 Alkylene -CN, -C 0-6 Alkylene-OR a 、-C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0103] m = 0, 1, 2, or 3;

[0104] Wherein R is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R on the same carbon atom form C=O, C=S, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; or two R on adjacent atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0105] R' is selected from H, D, halogen, CN, OR a NR b Rc 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, preferably H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0106] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group;

[0107] Among them, ring A, R1, R2, R, R', R a 、R b and R c Each group in may be optionally substituted by D up to full deuteration.

[0108] Z1, Z2, and Z3

[0109] In one embodiment, Z1 is N, and Z2 and Z3 are independently selected from CD or CH; in another embodiment, Z2 is N, and Z1 and Z3 are independently selected from CD or CH; in another embodiment, Z3 is N, and Z1 and Z2 are independently selected from CD or CH; in another embodiment, Z1 and Z2 are N, and Z3 is selected from CD or CH; in another embodiment, Z1 and Z3 are N, and Z2 is selected from CD or CH; in another embodiment, Z2 and Z3 are N, and Z1 is selected from CD or CH; in another embodiment, Z1, Z2 and Z3 are all N.

[0110] In a more specific embodiment, Selected from the following:

[0111] Ring A

[0112] In one embodiment, ring A is phenyl; in another embodiment, ring A is a 5-6 membered heteroaryl, preferably a 5-membered heteroaryl.

[0113] In a more specific embodiment, Ring A is selected from

[0114] In another more specific embodiment, Ring A is selected from Preferred More preferably

[0115] R1, R and R'

[0116] In one embodiment, R1 is selected from H, D, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; In another embodiment, R1 is selected from C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; In another embodiment, R1 is selected from 4-7 membered heterocyclic group, C 6-10 aryl or 5-6 membered heteroaryl; in another embodiment, R1 is selected from phenyl, pyrrolidinyl, pyrazolidinyl, piperidinyl or pyridonyl; in another embodiment, R1 is H; in another embodiment, R1 is D; in another embodiment, R1 is C 3-10 In another embodiment, R1 is a 4-10 membered heterocyclic group; In another embodiment, R1 is a C 6-10 Aryl; in another embodiment, R1 is a 5-10 membered heteroaryl.

[0117] In the above embodiment, R1 is substituted with 1 R substituent; in the above embodiment, R1 is substituted with 2 R substituents; in the above embodiment, R1 is substituted with 3 R substituents; in the above embodiment, R1 is substituted with 4 R substituents; in the above embodiment, R1 is substituted with 5 R substituents; in the above embodiment, R1 is substituted with 6 R substituents; in the above embodiment, R1 is substituted with 7 R substituents; in the above embodiment, R1 is substituted with 8 R substituents; in the above embodiment, R1 is substituted with 9 R substituents; in the above embodiment, R1 is substituted with 10 R substituents.

[0118] In a more specific embodiment, R is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 In another more specific embodiment, R is selected from halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 In another more specific embodiment, R is H; in another more specific embodiment, R is D; in another more specific embodiment, R is halogen; in another more specific embodiment, R is CN; in another more specific embodiment, R is OR a In another more specific embodiment, R is NR b R c In another more specific embodiment, R is C 1-6 In another more specific embodiment, R is C 1-6 In another more specific embodiment, two R on the same carbon atom form C=O with the carbon atom; in another more specific embodiment, two R on the same carbon atom form C=S with the carbon atom; in another more specific embodiment, two R on the same carbon atom form C=O with the carbon atom; 3-8 Cycloalkyl, preferably C 3-6 In another more specific embodiment, two R on the same carbon atom form a 4-7 membered heterocyclic group with the carbon atom; in another more specific embodiment, two R on adjacent atoms form a C 3-8 Cycloalkyl, preferably C 3-6 Cycloalkyl; in another more specific embodiment, two R on adjacent atoms form a 4-7 membered heterocyclic group with the atom, preferably a 5-6 membered heterocyclic group; in another more specific embodiment, two R on adjacent atoms form a C6-10 Aryl, preferably phenyl; in another more specific embodiment, two R on adjacent atoms form a 5-10 membered heteroaryl with the atom, preferably a 5-6 membered heteroaryl; in another more specific embodiment, two R on adjacent atoms form a cyclopentenyl, phenyl, thienyl or pyridyl with the atom.

[0119] In the above embodiment, R is substituted with one R' substituent; in the above embodiment, R is substituted with two R' substituents; in the above embodiment, R is substituted with three R' substituents; in the above embodiment, R is substituted with four R' substituents;

[0120] In a more specific embodiment, R' is H; in another more specific embodiment, R' is D; in another more specific embodiment, R' is halogen; in another more specific embodiment, R' is CN; in another more specific embodiment, R' is OR a In another more specific embodiment, R' is NR b R c In another more specific embodiment, R' is C(O)OR a In another more specific embodiment, R' is C(O)NR b R c In another more specific embodiment, R' is S(O)R a In another more specific embodiment, R' is S(O)2R a In another more specific embodiment, R' is C 1-6 Alkyl; in another more specific embodiment, R' is C 1-6 In another more specific embodiment, R' is C 2-6 In another more specific embodiment, R' is C 2-6 Alkynyl; in another more specific embodiment, R' is C 3-10 In another more specific embodiment, R' is a 4-10 membered heterocyclyl; In another more specific embodiment, R' is C 6-10 Aryl; in another more specific embodiment, R' is a 5-10 membered heteroaryl; in another more specific embodiment, two R's on the same or different atoms form a heteroaryl group with the atom optionally substituted by one or more D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl substituted C 3-8 Cycloalkyl (preferably C 3-6 In another more specific embodiment, two R's on the same or different atoms form a cycloalkyl group with the atoms optionally substituted by one or more D, halogen, C 1-6Alkyl or C 1-6 4-7 membered heterocyclic group (preferably 5-6 membered heterocyclic group) substituted by haloalkyl; in another more specific embodiment, R' is optionally substituted by one or more D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl substituted C 6-10 Aryl (preferably phenyl); in another more specific embodiment, R' is optionally substituted by one or more D, halogen, C 1-6 Alkyl or C 1-6 5-10 membered heteroaryl (preferably 5-6 membered heteroaryl) substituted with haloalkyl.

[0121] R2

[0122] In one embodiment, R2 is selected from H, D, -C 0-6 Alkylene-halogen, -C 0-6 Alkylene -CN, -C 0-6 Alkylene-OR a 、 -C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclyl; In another embodiment, R2 is selected from H, halogen, CN, -C 0-6 Alkylene-OR a 、-C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-8 In another embodiment, R2 is selected from H, -C 0-6 Alkylene-OR a 、C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl; in another embodiment, R2 is selected from H, F, Cl, Br, CH2CH2OH, Me, Et, Pr, iPr, CF3 or cyclopropyl; in another embodiment, R2 is selected from C 1-6 Alkyl or C 1-6 haloalkyl, preferably Me; in another embodiment, R2 is H; in another embodiment, R2 is D; in another embodiment, R2 is -C 0-6 Alkylene-halogen, preferably halogen; in another embodiment, R2 is -C 0-6Alkylene-CN, preferably CN; in another embodiment, R2 is -C 0- 6-alkylene-OR a , preferably -OR a In another embodiment, R2 is -C 0-6 Alkylene-NR b R c NR is preferred b R c In another embodiment, R2 is C 1-6 Alkyl; In another embodiment, R2 is C 1-6 In another embodiment, R2 is C 3-8 In another embodiment, R2 is a 4-7 membered heterocyclyl.

[0123] m

[0124] In one embodiment, m=0; in another embodiment, m=1; in another embodiment, m=2; and in another embodiment, m=3.

[0125] Any technical solution or any combination thereof in any of the above specific embodiments may be combined with any technical solution or any combination thereof in any other specific embodiment. For example, any technical solution or any combination thereof for Ring A may be combined with any technical solution or any combination thereof for Z1, Z2, Z3, R1, R2, and m, etc. The present invention is intended to include all combinations of these technical solutions, but due to space limitations, they are not listed one by one.

[0126] In a more specific embodiment, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof:

[0127] in:

[0128] Z1, Z2 and Z3 are independently selected from N, CD or CH, and at least one of them is N;

[0129] Ring A is phenyl or a 5-6 membered heteroaryl group;

[0130] R1 is selected from H, D, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents;

[0131] R2 is selected from H, D, -C 0-6 Alkylene-halogen, -C0-6 Alkylene -CN, -C 0-6 Alkylene-OR a 、-C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0132] m = 0, 1, 2, or 3;

[0133] Wherein R is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R on the same carbon atom form C=O, C=S, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; or two R on adjacent atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0134] R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, preferably H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, which is optionally substituted by one or more D, halogen, C 1-6 Alkyl or C 1-6 haloalkyl substitution;

[0135] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group;

[0136] Among them, ring A, R1, R2, R, R', R a 、R b and R c Each group in may be optionally substituted by D up to full deuteration.

[0137] In a more specific embodiment, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof:

[0138] in:

[0139] Z1, Z2 and Z3 are independently selected from N, CD or CH, and at least one of them is N;

[0140] Ring A is phenyl or a 5-6 membered heteroaryl group;

[0141] R1 is selected from H, D, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents;

[0142] R2 is selected from H, D, -C 0-6 Alkylene-halogen, -C 0-6 Alkylene -CN, -C 0-6 Alkylene-OR a 、-C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0143] m = 0, 1, 2, or 3;

[0144] Wherein R is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R on the same carbon atom form C=O, C=S, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; or two R on adjacent atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0145] R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, preferably H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0146] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group;

[0147] Among them, ring A, R1, R2, R, R', R a 、R b and R cEach group in may be optionally substituted by D up to full deuteration.

[0148] In a more specific embodiment, the present invention provides a compound of formula (I) as described above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein Ring A is a 5-6 membered heteroaryl group;

[0149] Preferably selected from the following:

[0150] More preferably, they are selected from the following:

[0151] More preferably

[0152] wherein R1 and R2 are as defined above.

[0153] In a more specific embodiment, the present invention provides a compound of formula (I) as described above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R2 is selected from H, halogen, CN, -C 0-6 Alkylene-OR a 、-C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-8 Cycloalkyl; preferably selected from H, -C 0-6 Alkylene-OR a 、C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl; more preferably selected from H, F, Cl, Br, CH2CH2OH, Me, Et, Pr, iPr, CF3 or cyclopropyl; more preferably C 1-6 Alkyl or C 1-6 Haloalkyl, especially Me.

[0154] In a more specific embodiment, the present invention provides a compound of formula (I) as described above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R1 is selected from C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; preferably selected from 4-7 membered heterocyclic group, C 6-10 Aryl or 5-6 membered heteroaryl; more preferably selected from phenyl, pyrrolidinyl, pyrazolidinyl, piperidinyl or pyridonyl.

[0155] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R is selected from halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R on the same carbon atom form C=O, C=S or C=O with the carbon atom; 3-6 Cycloalkyl; or two R on adjacent atoms form a C 3-6 Cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, for example cyclopentenyl, phenyl, thienyl or pyridyl.

[0156] In a more specific embodiment, the present invention provides a compound of formula (I) as described above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3- 10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; preferably, R' is selected from H, D, halogen, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; preferably, R' is selected from H, D, halogen, CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 6-10 Aryl or 5-10 membered heteroaryl; preferably, R' is selected from H, D, halogen, CN, OR a NR b R c、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-6 Cycloalkyl or 5-6 membered heterocyclic group.

[0157] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, which has the following general formula:

[0158] in,

[0159] represents a single bond or a double bond;

[0160] X is selected from NR N , CR 2b R 2b '、CR 2b R 2b '-CR 2b R 2b ' or CR 2b =CR 2b ';

[0161] Y1 is selected from N or CR Y1 ;

[0162] Y2 is selected from N or CR Y2 ;

[0163] Y3 is selected from N or CR Y3 ;

[0164] Y4 is selected from N or CR Y4 ;

[0165] where R N Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;

[0166] R 1a 、R 2a 、R 3a 、R 4a 、R 5a 、R 1b 、R 1b '、R 2b 、R 2b '、R 3b and R 4b has the same definition as R above;

[0167] R Y1 、R Y2、R Y3 and R Y4 has the same definition as R' above;

[0168] The other groups are as defined above.

[0169] In a more specific embodiment, the present invention provides the above-mentioned compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, which has the following general formula:

[0170] in,

[0171] R2 is selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0172] R 1a Selected from H, D, halogen, CN, OR a or NR b R c ;

[0173] R 2a is selected from H, D, halogen or CN;

[0174] R 3a Selected from H or D;

[0175] R 4a Selected from OR a or NR b R c ;

[0176] R 5a Selected from H, D or CN;

[0177] Or, R 3a 、R 4a and the carbon atom to which they are attached form a 4-6 membered heterocyclyl or a 5-6 membered heteroaryl, which is optionally substituted with 1, 2, 3 or 4 R' substituents;

[0178] Wherein R' is selected from H, D, C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0179] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

[0180] In a more specific embodiment, the present invention provides a compound of formula (III-1), (III-2) or (III-3) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0181] R2 is selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;

[0182] R 1a is halogen, preferably F;

[0183] R 2a is selected from H, D or halogen;

[0184] R 3a H or D;

[0185] R 4a OR a ;

[0186] R 5a For CN;

[0187] Or, R 3a 、R 4a and the carbon atom to which they are attached form a furanyl or dihydrofuranyl group, which is optionally substituted with 1, 2, 3, or 4 R' substituents;

[0188] Wherein R' is selected from H, D, C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-6 Cycloalkyl or 5-6 membered heterocyclic group;

[0189] R a Selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl or 4-7 membered heterocyclic group.

[0190] In a more specific embodiment, the present invention provides a compound of formula (III-1), (III-2) or (III-3) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0191] R2 is selected from H, C 1-4 Alkyl or C 1-4 alkyl halide;

[0192] R 1a is halogen, preferably F;

[0193] R 2a is selected from H, D or halogen;

[0194] R 3a H or D;

[0195] R 4a OR a ;

[0196] R 5a For CN;

[0197] Or, R 3a 、R 4a and the carbon atom to which they are attached form a dihydrofuranyl group substituted with 1, 2, 3, or 4 R' substituents;

[0198] Wherein R' is selected from H, D, C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-6 Cycloalkyl or 5-6 membered heterocyclic group, preferably cyclopropyl;

[0199] R a Selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl or 5-6 membered heterocyclic group.

[0200] In a more specific embodiment, the present invention provides a compound of formula (III-1), (III-2) or (III-3) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0201] R2 is Me;

[0202] R 1a is F;

[0203] R 2ais H or Cl;

[0204] R 3a 、R 4a and the carbon atom to which they are attached form a dihydrofuranyl group substituted with 1, 2, 3, or 4 R' substituents;

[0205] R 5a For CN;

[0206] wherein R' is selected from H or Me, or two R' on the same or different atoms form a cyclopropyl group with the atom.

[0207] In a more specific embodiment, the present invention provides the above-mentioned compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, which has the following general formula:

[0208] in,

[0209] represents a single bond or a double bond;

[0210] X is selected from NR N , CR 2b R 2b '、CR 2b R 2b '-CR 2b R 2b ' or CR 2b =CR 2b ';

[0211] R2 is selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0212] R 1b and R 1b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0213] R 3b and R 4b Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 haloalkyl; or R 3b 、R 4band the carbon atoms to which they are attached form C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0214] where R N Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;

[0215] R 2b and R 2b 'Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 haloalkyl; or R on the same or different atoms 2b and R 2b ' and the carbon atoms to which they are connected form C 3-6 Cycloalkyl or 4-7 membered heterocyclic group; or R 2b ' and R 3b and the carbon atoms to which they are attached form C 6-10 Aryl or 5-10 membered heteroaryl;

[0216] R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0217] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

[0218] In a more specific embodiment, the present invention provides a compound of formula (IV-1) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0219] Indicates a single bond or a double bond;

[0220] X is selected from NR N , CR 2b R 2b ' or CR 2b =CR 2b ';

[0221] R2 is selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;

[0222] R 1b and R 1b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0223] R 3b and R 4b Independently selected from H, D, OR a NR b R c 、C 1-6 Alkyl or C 1-6 haloalkyl; or R 3b 、R 4b and the carbon atoms to which they are attached form C 3-6 cycloalkyl, 4-7 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0224] where R N Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;

[0225] R 2b and R 2b 'Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 haloalkyl; or R on the same or different atoms 2b and R 2b ' and the carbon atoms to which they are connected form C 3-6 Cycloalkyl; or R 2b ' and R 3b and the carbon atoms to which they are attached form a phenyl group or a 5-6 membered heteroaryl group;

[0226] R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide;

[0227] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

[0228] In a more specific embodiment, the present invention provides the above-mentioned compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, which has the following general formula:

[0229] in,

[0230] X is selected from NR N or CR 2b R 2b ';

[0231] R2 is selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;

[0232] R 1b and R 1b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0233] Y1 is selected from N or CR Y1 ;

[0234] Y2 is selected from N or CR Y2 ;

[0235] Y3 is selected from N or CR Y3 ;

[0236] Y4 is selected from N or CR Y4 ;

[0237] where R N Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;

[0238] R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 haloalkyl; or R 2b and R 2b ' and the carbon atoms to which they are connected form C 3-6 Cycloalkyl;

[0239] R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide;

[0240] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

[0241] In a more specific embodiment, the present invention provides a compound of formula (IV-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0242] X is selected from NR N or CR 2b R 2b ';

[0243] R2 is selected from H, C 1-4 Alkyl or C 1-4 alkyl halide;

[0244] R 1b and R 1b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R1b 、R 1b 'and the carbon atoms to which they are attached form C=O;

[0245] Y1 is selected from N or CR Y1 ;

[0246] Y2 is selected from N or CR Y2 ;

[0247] Y3 is selected from N or CR Y3 ;

[0248] Y4 is selected from N or CR Y4 ;

[0249] where R N Selected from H, C 1-4 Alkyl or C 1-4 alkyl halide;

[0250] R 2b and R 2b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 2b and R 2b ' and the carbon atoms to which they are connected form C 3-6 Cycloalkyl;

[0251] R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide;

[0252] R a 、R b and R c Independently selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl, or R b and R c and the nitrogen atom to which they are attached form a 5-6 membered heterocyclic group.

[0253] In a more specific embodiment, the present invention provides a compound of formula (IV-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0254] X is selected from NR N or CR 2b R2b ';

[0255] R2 is Me;

[0256] R 1b and R 1b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O;

[0257] Y1 is selected from N or CR Y1 ;

[0258] Y2 is selected from N or CR Y2 ;

[0259] Y3 is selected from N or CR Y3 ;

[0260] Y4 is selected from N or CR Y4 ;

[0261] where R N selected from H or Me;

[0262] R 2b and R 2b 'Independently selected from H or Me, or R 2b and R 2b 'and the carbon atom to which they are attached form a cyclopropyl group;

[0263] R Y1 、R Y2 、R Y3 and R Y4 Selected from H, F, CN, Me, CF3 or OMe.

[0264] In a more specific embodiment, the present invention provides the above-mentioned compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, which has the following general formula:

[0265] in,

[0266] Indicates a single bond or a double bond;

[0267] R2 is selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;

[0268] R 1b and R 1b 'Independently selected from H, C 1-6 Alkyl or C1-6 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0269] R 2b and R 2b 'Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide;

[0270] R 3b is selected from H, D, halogen or CN;

[0271] R 4b Selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide;

[0272] or R 2b ' and R 3b and the carbon atoms to which they are attached form a phenyl group or a 5-6 membered heteroaryl group;

[0273] or R 3b 、R 4b and the carbon atoms to which they are attached form C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0274] R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl or 4-7 membered heterocyclic group;

[0275] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

[0276] In a more specific embodiment, the present invention provides a compound of formula (IV-3) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0277] Indicates a single bond or a double bond;

[0278] R2 is selected from H, C 1-4 Alkyl or C 1-4 alkyl halide;

[0279] R 1b and R 1b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O;

[0280] R 2b and R 2b 'Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-4 Alkyl or C 1-4 alkyl halide;

[0281] R 3b Selected from H or D;

[0282] R 4b Selected from H, D, OR a NR b R c 、C 1-4 Alkyl or C 1-4 alkyl halide;

[0283] or R 2b ' and R 3b and the carbon atom to which they are attached forms a phenyl group;

[0284] or R 3b 、R 4b and the carbon atoms to which they are attached form C 3-6 cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0285] R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide;

[0286] R a 、R b and R c Independently selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.

[0287] In a more specific embodiment, the present invention provides a compound of formula (IV-3) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0288] represents a single bond or a double bond;

[0289] R2 is Me;

[0290] R 1b and R 1b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O;

[0291] R 2b Selected from H, D, F, Cl, Br, I, Me or CF3;

[0292] R 2b ' is selected from H, D, F, Cl, Br, I, Me, CF3 or OMe;

[0293] R 3b H or D;

[0294] R 4b is selected from H, D, Me, OMe or O-cyclopropyl;

[0295] Or, R 3b 、R 4b and the carbon atom to which they are attached forms a phenyl, cyclopentenyl, or thienyl group;

[0296] Or, R 2b '、R 3b and the carbon atom to which they are attached form a phenyl group.

[0297] In a more specific embodiment, the present invention provides the above-mentioned compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, which has the following general formula:

[0298] in:

[0299] R1 and R2 are as defined in any one of claims 1 and 3-6;

[0300] Preferably,

[0301] R1 is a 4-7 membered heterocyclyl group, which is optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents;

[0302] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0303] Wherein R is selected from H, D, halogen, CN, C 1-6 Alkyl or C 1-6 haloalkyl; or two R on the same carbon atom form C=O or C=S with the carbon atom; or two R on adjacent atoms form phenyl or 5-6 membered heteroaryl with the atom, which is optionally substituted with 1, 2, 3 or 4 R' substituents;

[0304] R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0305] where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl.

[0306] In a more specific embodiment, the present invention provides a compound of formula (V) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0307] R1 is a 5-6 membered heterocyclyl group, which is optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents;

[0308] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0309] Wherein R is selected from H, D, halogen, CN, C 1-6 Alkyl or C 1-6 haloalkyl; or two R on the same carbon atom form C=O or C=S with that carbon atom; or two R on adjacent atoms form phenyl with said atom, which is optionally substituted with 1, 2, 3 or 4 R' substituents;

[0310] R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl;

[0311] where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

[0312] In a more specific embodiment, the present invention provides a compound of formula (V) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0313] R1 is selected from pyrrolidinyl or piperidinyl, optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents;

[0314] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0315] Wherein R is selected from H, D, halogen, CN, C 1-6 Alkyl or C 1-6haloalkyl; or two R on the same carbon atom form C=O with the carbon atom; or two R on adjacent atoms form phenyl with the atom, which is optionally substituted with 1, 2, 3 or 4 R' substituents;

[0316] R' is selected from H, D, halogen, CN, C 1-6 Alkyl, C 1-6 halogenated alkyl, phenyl or 5-6 membered heteroaryl.

[0317] In a more specific embodiment, the present invention provides the above-mentioned compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, which has the following general formula:

[0318] in:

[0319] Indicates a single bond or a double bond;

[0320] X is selected from CR 2b R 2b '、CR 2b R 2b '-CR 2b R 2b ' or CR 2b =CR 2b ';

[0321] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0322] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0323] R 3b 、R 4b and the carbon atoms to which they are attached form C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents;

[0324] R 2b and R 2b 'Independently selected from H, D, halogen, CN, C 1-6 Alkyl or C 1-6 alkyl halide;

[0325] R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b Rc 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0326] where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl.

[0327] In a more specific embodiment, the present invention provides a compound of formula (VI-1) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0328] represents a double bond;

[0329] X is selected from CR 2b R 2b '、CR 2b R 2b '-CR 2b R 2b ' or CR 2b =CR 2b ';

[0330] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0331] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0332] R 3b 、R 4b and the carbon atom to which they are attached form a phenyl group, which is optionally substituted with 1, 2, 3, or 4 R' substituents;

[0333] R 2b and R 2b 'Independently selected from H, D, halogen, CN, C 1-6 Alkyl or C 1-6 alkyl halide;

[0334] R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl;

[0335] where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl.

[0336] In a more specific embodiment, the present invention provides a compound of formula (VI-1) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0337] represents a double bond;

[0338] X is selected from CR 2b R 2b ' or CR 2b R 2b '-CR 2b R 2b ';

[0339] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0340] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O;

[0341] R 3b 、R 4b and the carbon atom to which they are attached form a phenyl group, which is optionally substituted with 1, 2, 3, or 4 R' substituents;

[0342] R 2b and R 2b 'Independently selected from H or D;

[0343] R' is selected from H, D, halogen, CN, C 1-6 Alkyl, C 1-6 halogenated alkyl, phenyl or 5-6 membered heteroaryl.

[0344] In a more specific embodiment, the present invention provides the above-mentioned compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, which has the following general formula:

[0345] in:

[0346] X is CR 2b R 2b ';

[0347] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0348] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0349] Y1 is selected from N or CR Y1 ;

[0350] Y2 is selected from N or CR Y2 ;

[0351] Y3 is selected from N or CR Y3 ;

[0352] Y4 is selected from N or CR Y4 ;

[0353] R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0354] R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0355] where R a 、R b and Rc Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl.

[0356] In a more specific embodiment, the present invention provides a compound of formula (VI-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0357] X is CR 2b R 2b ';

[0358] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0359] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0360] Y1 is selected from N or CR Y1 ;

[0361] Y2 is selected from N or CR Y2 ;

[0362] Y3 is selected from N or CR Y3 ;

[0363] Y4 is selected from N or CR Y4 ;

[0364] R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0365] R Y1 、R Y2 、R Y3 and R Y4 R' is independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl;

[0366] where R a、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

[0367] In a more specific embodiment, the present invention provides a compound of formula (VI-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0368] X is CR 2b R 2b ';

[0369] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0370] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O;

[0371] Y1 is CR Y1 ;

[0372] Y2 is CR Y2 ;

[0373] Y3 is CR Y3 ;

[0374] Y4 is CR Y4 ;

[0375] R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0376] R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, CN, C 1-6 Alkyl, C 1-6 halogenated alkyl, phenyl or 5-6 membered heteroaryl.

[0377] In a more specific embodiment, the present invention provides the above-mentioned compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, which has the following general formula:

[0378] in:

[0379] X is CR 2b R 2b ';

[0380] R2 is selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl or 4-7 membered heterocyclic group;

[0381] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0382] Y1 is CR Y1 ;

[0383] Y2 is CR Y2 ;

[0384] Y3 is CR Y3 ;

[0385] Y4 is CR Y4 ;

[0386] R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0387] R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2- 6 alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0388] or R Y1 and R Y2 、R Y2 and R Y3 、R Y3 and R Y4 , and the atoms they connect together form C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, which is optionally substituted by one or more D, halogen, C1-6 Alkyl or C 1-6 haloalkyl substitution;

[0389] where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

[0390] In a more specific embodiment, the present invention provides a compound of formula (VI-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0391] X is CR 2b R 2b ';

[0392] R2 is Me, Et or cyclopropyl;

[0393] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O;

[0394] Y1 is CR Y1 ;

[0395] Y2 is CR Y2 ;

[0396] Y3 is CR Y3 ;

[0397] Y4 is CR Y4 ;

[0398] R 2b and R 2b 'Independently selected from H or D;

[0399] R Y1 Selected from H, D, Cl, F, CN, Me, CF3 or OMe;

[0400] R Y2 is selected from H, D, Me, Et, iPr, CF3, cyclopropyl, OMe, OEt, OiPr, OCF3, O-cyclopropyl, prop-1-en-2-yl or phenyl;

[0401] R Y3 is selected from H, D, Cl, F, Me, Et, iPr, CF3, cyclopropyl, prop-1-en-2-yl, OMe or O-cyclopropyl;

[0402] R Y4 Selected from H, D or Me;

[0403] or R Y1 and R Y2 、R Y2 and R Y3 、R Y3 and R Y4 , and the atoms they connect together form C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, which is optionally substituted by one or more D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl substitution.

[0404] In a more specific embodiment, the present invention provides a compound of formula (VI-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0405] X is CR 2b R 2b ';

[0406] R2 is selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl or 4-7 membered heterocyclic group;

[0407] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0408] Y1 is CR Y1 ;

[0409] Y2 is CR Y2 ;

[0410] Y3 is CR Y3 ;

[0411] Y4 is CR Y4 ;

[0412] R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0413] R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, OR a NRb R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0414] where R Y1 and R Y3 At least one of them is not H or D;

[0415] where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

[0416] In a more specific embodiment, the present invention provides a compound of formula (VI-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0417] X is CR 2b R 2b ';

[0418] R2 is selected from C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl;

[0419] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0420] Y1 is CR Y1 ;

[0421] Y2 is CR Y2 ;

[0422] Y3 is CR Y3 ;

[0423] Y4 is CR Y4 ;

[0424] R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0425] R Y1 and R Y3 Independently selected from H, D, halogen, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl or 4-7 membered heterocyclic group;

[0426] R Y2 and R Y4 Independently selected from H, D, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0427] where R Y1 and R Y3 At least one of them is not H or D;

[0428] where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

[0429] In a more specific embodiment, the present invention provides a compound of formula (VI-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0430] X is CR 2b R 2b ';

[0431] R2 is Me, Et or cyclopropyl;

[0432] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O;

[0433] Y1 is CR Y1 ;

[0434] Y2 is CR Y2 ;

[0435] Y3 is CR Y3 ;

[0436] Y4 is CR Y4 ;

[0437] R 2b and R 2b 'Independently selected from H or D;

[0438] R Y1 Selected from H, D, Cl, F, Me, CF3 or OMe;

[0439] R Y2 is selected from H, D, Et, iPr, OiPr, O-cyclopropyl or prop-1-en-2-yl;

[0440] R Y3 is selected from H, D, Cl, F, Me, Et, iPr, CF3, cyclopropyl, prop-1-en-2-yl, OMe or O-cyclopropyl;

[0441] R Y4 Selected from H or D;

[0442] where R Y1 and R Y3 At least one of them is not H or D.

[0443] In a more specific embodiment, the present invention provides a compound of formula (VI-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0444] X is CR 2b R 2b ';

[0445] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0446] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S;

[0447] Y1 is CR Y1 ;

[0448] Y2 is CR Y2 ;

[0449] Y3 is CR Y3 ;

[0450] Y4 is CR Y4 ;

[0451] R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0452] R Y1 and R Y3 Independently selected from H, D, halogen, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl or 4-7 membered heterocyclic group;

[0453] R Y2 and R Y4 Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0454] where R Y1 and R Y3 At least one of them is not H or D;

[0455] where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

[0456] In a more specific embodiment, the present invention provides a compound of formula (VI-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0457] X is CR 2b R 2b ';

[0458] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0459] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O;

[0460] Y1 is CR Y1 ;

[0461] Y2 is CR Y2 ;

[0462] Y3 is CR Y3 ;

[0463] Y4 is CR Y4 ;

[0464] R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0465] R Y1 Selected from H, D, halogen, C 1-6 Alkyl or C 1-6 alkyl halide;

[0466] R Y2 Selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0467] R Y3 Selected from H, D, halogen, OR a 、C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl;

[0468] R Y4 Selected from H or D;

[0469] where R Y1 and R Y3 At least one of them is not H or D;

[0470] where R a Selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.

[0471] In a more specific embodiment, the present invention provides a compound of formula (VI-2) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0472] X is CR 2b R 2b ';

[0473] R2 is Me;

[0474] R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O;

[0475] Y1 is CR Y1 ;

[0476] Y2 is CR Y2 ;

[0477] Y3 is CR Y3 ;

[0478] Y4 is CR Y4 ;

[0479] R 2b and R 2b 'Independently selected from H or D;

[0480] R Y1 Selected from H, D, Cl, F, Me or CF3;

[0481] R Y2 selected from H, D or Et;

[0482] R Y3 is selected from H, D, Cl, F, Me, Et, OMe or cyclopropyl;

[0483] R Y4 Selected from H or D;

[0484] where R Y1 and R Y3 At least one of them is not H or D.

[0485] In a more specific embodiment, the present invention provides the above-mentioned compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, which has the following general formula:

[0486] in,

[0487] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0488] R 1a Selected from H, D, halogen, CN, OR a or NR b R c ;

[0489] R 2a is selected from H, D, halogen or CN;

[0490] R 3a Selected from H or D;

[0491] R 4a Selected from OR a or NR b R c ;

[0492] R 5aSelected from H, D or CN;

[0493] Or, R 3a 、R 4a and the carbon atom to which they are attached form a 4-6 membered heterocyclyl or a 5-6 membered heteroaryl, which is optionally substituted with 1, 2, 3 or 4 R' substituents;

[0494] Wherein R' is selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide;

[0495] R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

[0496] In a more specific embodiment, the present invention provides a compound of formula (VII) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0497] R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide;

[0498] R 1a is halogen, preferably F;

[0499] R 2a is selected from H, D or halogen;

[0500] R 3a H or D;

[0501] R 4a OR a ;

[0502] R 5a For CN;

[0503] Or, R 3a 、R 4a and the carbon atom to which they are attached form a furanyl or dihydrofuranyl group, which is optionally substituted with 1, 2, 3, or 4 R' substituents;

[0504] Wherein R' is selected from H, D, C 1-6Alkyl or C 1-6 alkyl halide;

[0505] R a Selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl or 4-7 membered heterocyclic group.

[0506] In a more specific embodiment, the present invention provides a compound of formula (VII) above, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein,

[0507] R2 is selected from C 1-4 Alkyl or C 1-4 alkyl halide;

[0508] R 1a is halogen, preferably F;

[0509] R 2a is selected from H, D or halogen;

[0510] R 3a H or D;

[0511] R 4a OR a ;

[0512] R 5a For CN;

[0513] where R a Selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl or 5-6 membered heterocyclic group.

[0514] In a more specific embodiment, the present invention provides a compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein the compound is selected from Table 1 and Table 2 below.

[0515] Table 1: Representative compounds of the present invention

[0516] Table 2: Preferred representative compounds of the present invention

[0517] The compounds of the present invention may include one or more asymmetric centers and may therefore exist in a variety of stereoisomeric forms, for example, enantiomers and / or diastereomeric forms. For example, the compounds of the present invention may be individual enantiomers, diastereomers, or geometric isomers (e.g., cis and trans isomers), or may be in the form of mixtures of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis.

[0518] The compounds of the present invention may exist as tautomers. Tautomers are functional group isomers resulting from the rapid shift of an atom between two positions in a molecule. Tautomers are a special type of functional group isomer. A pair of tautomers can convert between each other, but the more stable isomer usually predominates. The most prominent examples are the enol and keto tautomers.

[0519] Those skilled in the art will appreciate that organic compounds can form complexes with solvents in which they react or from which they precipitate or crystallize. These complexes are referred to as "solvates." When the solvent is water, the complex is referred to as a "hydrate." The present invention encompasses all solvates of the compounds of the present invention.

[0520] The term "solvate" refers to a form of a compound or its salt that is combined with a solvent, usually formed by a solvolysis reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, etc. The compounds described herein can be prepared, for example, in a crystalline form and can be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include stoichiometric solvates and non-stoichiometric solvates. In some cases, the solvate will be able to separate, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvate" includes solvates in the solution state and separable solvates. Representative solvates include hydrates, ethanolates, and methanolates.

[0521] The term "hydrate" refers to a compound that is combined with water. Generally, the ratio of the number of water molecules contained in the hydrate of a compound to the number of molecules of the compound in the hydrate is determined. Therefore, the hydrate of a compound can be represented by the general formula R×x H2O, for example, where R is the compound and x is a number greater than 0. A given compound can form more than one type of hydrate, including, for example, monohydrates (x is 1), lower hydrates (x is a number greater than 0 and less than 1, for example, hemihydrates (R×0.5H2O)) and polyhydrates (x is a number greater than 1, for example, dihydrates (R×2H2O) and hexahydrates (R×6H2O)).

[0522] The compounds of the present invention can be in amorphous or crystalline form (polymorph). In addition, the compounds of the present invention can exist in one or more crystalline forms. Therefore, the present invention includes all amorphous or crystalline forms of the compounds of the present invention within its scope. The term "polymorph" refers to the crystalline form (or its salt, hydrate or solvate) of a compound with a specific crystal packing arrangement. All polymorphs have the same elemental composition. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, photoelectric properties, stability and solubility. Recrystallization solvent, crystallization rate, storage temperature and other factors can cause one crystalline form to dominate. The various polymorphs of a compound can be prepared by crystallization under different conditions.

[0523] The present invention also includes isotopically labeled compounds (isotopic variants) which are identical to those described in formula (I) but for which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be introduced into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, for example 2 H. 3 H. 13 C. 11 C. 14 C.15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Compounds of the present invention containing the above-mentioned isotopes and / or other isotopes of other atoms, their prodrugs and pharmaceutically acceptable salts of the compounds or prodrugs are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, such as those in which radioactive isotopes (e.g. 3 H and 14 C) can be used in drug and / or substrate tissue distribution assays. 3 H and carbon-14, i.e. 14 C isotopes are particularly preferred because they are easy to prepare and detect. 2 H, because greater metabolic stability can provide therapeutic benefits, such as prolonged in vivo half-life or reduced dosage requirements, and thus may be preferred in some cases. Isotopically labeled compounds of formula (A) of the present invention and prodrugs thereof can generally be prepared by substituting readily available isotopically labeled reagents for non-isotopically labeled reagents when carrying out the processes disclosed in the following schemes and / or the Examples and Preparations.

[0524] In addition, prodrugs are also included in the context of the present invention. The term "prodrug" as used herein refers to a compound that is converted in vivo, for example by hydrolysis in the blood, into its active form that has a medical effect. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the ACSSymposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and D. Fleisher, S. Ramon and H. Barbra, "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19 (2) 115-130, each of which is incorporated herein by reference.

[0525] A prodrug is any covalently bonded compound of the present invention that releases the parent compound in vivo when such a prodrug is administered to a patient. Prodrugs are typically prepared by modifying functional groups in such a way that the modification can be cleaved to produce the parent compound by conventional manipulation or in vivo. Prodrugs include, for example, compounds of the present invention in which a hydroxyl, amino, or sulfhydryl group is bonded to any group that, when administered to a patient, can cleave to form a hydroxyl, amino, or sulfhydryl group. Thus, representative examples of prodrugs include, but are not limited to, acetate / amide, formate / amide, and benzoate / amide derivatives of the hydroxyl, sulfhydryl, and amino functional groups of compounds of formula (A). In addition, in the case of carboxylic acids (-COOH), esters such as methyl esters, ethyl esters, and the like can be used. Esters themselves can be active and / or can be hydrolyzed under human in vivo conditions. Suitable pharmaceutically acceptable in vivo hydrolyzable ester groups include those that readily decompose in the human body to release the parent acid or a salt thereof.

[0526] The present invention also provides a pharmaceutical preparation comprising a therapeutically effective amount of a compound of formula (A) or a therapeutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient thereof. All of these forms belong to the present invention.

[0527] Pharmaceutical compositions and kits

[0528] In another aspect, the present invention provides pharmaceutical compositions comprising a compound of the present invention (also referred to as an "active ingredient") and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises an effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a prophylactically effective amount of a compound of the present invention.

[0529] Pharmaceutically acceptable excipients used in the present invention refer to non-toxic carriers, adjuvants or vehicles that do not destroy the pharmacological activity of the compound formulated together. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the compositions of the present invention include (but are not limited to) ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and lanolin.

[0530] Suitable formulations for administering the compounds of the present invention will be readily apparent to those skilled in the art and include, for example, tablets, pills, capsules, suppositories, lozenges, troches, solutions (particularly solutions for injection (subcutaneous, intravenous, intramuscular) and infusion (injection)), elixirs, syrups, cachets, emulsions, inhalants, or dispersible powders. The content of the one or more pharmaceutically active compounds should be in the range of 0.1 to 90% by weight, preferably 0.5 to 50% by weight, of the composition as a whole, i.e., an amount sufficient to achieve the dosage range specified below. If necessary, the specified dosage may be administered several times a day.

[0531] The present invention also includes kits (e.g., pharmaceutical packaging). The kits provided may include a compound of the invention, other therapeutic agents, and first and second containers (e.g., vials, ampoules, bottles, syringes, and / or dispersible packaging or other suitable containers) containing the compound of the invention and other therapeutic agents. In some embodiments, the kit provided may also optionally include a third container containing a pharmaceutical excipient for diluting or suspending the compound of the invention and / or other therapeutic agents. In some embodiments, the compound of the invention and other therapeutic agents provided in the first and second containers are combined to form a unit dosage form.

[0532] Drug administration

[0533] Pharmaceutical compositions provided by the invention can be administered by many routes, including but not limited to: oral administration, parenteral administration, inhalation administration, topical administration, rectal administration, nasal administration, oral administration, vaginal administration, administration by implant or other modes of administration. For example, parenteral administration used herein includes subcutaneous administration, intradermal administration, intravenous administration, intramuscular administration, intraarticular administration, intraarterial administration, intrasynovial administration, intrasternal administration, intrathecal administration, intralesional administration, and intracranial injection or infusion technology.

[0534] Typically, an effective amount of the compounds provided herein is administered. The amount of compound actually administered can be determined by a physician based on the relevant circumstances, including the condition being treated, the route of administration selected, the compound actually administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[0535] When used to prevent the conditions described herein, the compounds provided herein are administered to a subject at risk of developing the condition, typically based on the advice and under the supervision of a physician, at dosage levels as described above. Subjects at risk of developing a particular condition typically include those with a family history of the condition, or those identified by genetic testing or screening as being particularly susceptible to developing the condition.

[0536] The pharmaceutical compositions provided herein can also be administered long-term ("chronic administration"). Long-term administration refers to administration of a compound or pharmaceutical composition thereof over an extended period of time, e.g., 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or administration can continue indefinitely, e.g., for the remainder of the subject's life. In some embodiments, long-term administration is intended to provide a constant level of the compound in the blood over an extended period of time, e.g., within the therapeutic window.

[0537] Various methods of administration can be used to further deliver the pharmaceutical composition of the present invention. For example, in some embodiments, the pharmaceutical composition can be administered by injection, for example, in order to increase the concentration of the compound in the blood to an effective level. The bolus dose depends on the target systemic level of the active ingredient by the body, for example, an intramuscular or subcutaneous bolus dose slowly releases the active ingredient, and the bolus (for example, by IV intravenous drip) delivered directly to the vein can be delivered more quickly so that the concentration of the active ingredient in the blood is rapidly increased to an effective level. In other embodiments, the pharmaceutical composition can be given in a continuous infusion form, for example, by IV intravenous drip, so as to provide a steady-state concentration of the active ingredient in the subject's body. In addition, in other embodiments, the pharmaceutical composition of the bolus dose can be first given, and then continuous infusion.

[0538] Oral compositions can be in the form of bulk liquid solutions or suspensions or bulk powders. However, more generally, in order to facilitate accurate dosing, the compositions are provided in unit dosage form. The term "unit dosage form" refers to a physically discrete unit suitable as a unit dose for human patients and other mammals, each unit containing a predetermined amount of active substance suitable for producing the desired therapeutic effect and a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or pills, tablets, capsules, etc. in the case of solid compositions. In such compositions, the compound is typically a minor component (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight), with the remainder being various carriers or excipients and processing aids useful for forming the desired dosage form.

[0539] For oral dosage, a representative regimen is one to five oral doses per day, particularly two to four oral doses, typically three oral doses. Using these dosage administration modes, each dose provides about 0.01 to about 20 mg / kg of the compound of the invention, with preferred doses each providing about 0.1 to about 10 mg / kg, particularly about 1 to about 5 mg / kg.

[0540] To provide blood levels similar to, or lower than, those obtained with an injectable dose, a transdermal dose is typically selected in an amount of about 0.01 to about 20% by weight, preferably about 0.1 to about 20% by weight, preferably about 0.1 to about 10% by weight, and more preferably about 0.5 to about 15% by weight.

[0541] From about 1 to about 120 hours, and particularly from 24 to 96 hours, the injected dose level is in the range of about 0.1 mg / kg / hour to at least 10 mg / kg / hour. To achieve adequate steady-state levels, a preload bolus of about 0.1 mg / kg to about 10 mg / kg or more may also be administered. For a 40 to 80 kg human patient, the maximum total dose may not exceed about 2 g / day.

[0542] Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous carrier and buffers, suspending and dispersing agents, colorants, flavorings, etc. Solid forms may include, for example, any of the following components, or compounds of a similar nature: binders such as microcrystalline cellulose, tragacanth, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavorings such as peppermint, methyl salicylate, or orange flavor.

[0543] Injectable compositions are typically based on sterile saline or phosphate buffered saline for injection, or other injectable excipients known in the art. As previously mentioned, in such compositions, the active compound is typically a minor component, often about 0.05 to 10% by weight, with the remainder being injectable excipients and the like.

[0544] Typically, transdermal compositions are formulated as topical ointments or creams containing the active ingredient. When formulated as an ointment, the active ingredient is typically combined with a paraffin or water-miscible ointment base. Alternatively, the active ingredient can be formulated into a cream together with, for example, an oil-in-water cream base. Such transdermal formulations are well known in the art and typically include other components that enhance the stable skin penetration of the active ingredient or formulation. All such known transdermal formulations and components are included within the scope provided by the present invention.

[0545] The compounds of the present invention may also be administered by transdermal devices.Thus, transdermal administration may be achieved using patches of the reservoir or porous membrane type, or various solid matrices.

[0546] The above components for oral administration, injection or topical administration are representative only. Other materials and processing techniques are described in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.

[0547] The compounds of the invention can also be administered in sustained release form or from a sustained release delivery system. Descriptions of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[0548] The present invention also relates to pharmaceutically acceptable formulations of the compounds of the present invention. In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α-, β-, and γ-cyclodextrins consisting of 6, 7, and 8 α-1,4-linked glucose units, respectively, which optionally include one or more substituents on the linked sugar portion, including but not limited to: methylated, hydroxyalkylated, acylated, and sulfoalkyl ether substitutions. In some embodiments, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, for example, sulfobutyl ether β-cyclodextrin, also known as Captisol. See, for example, US5,376,645. In some embodiments, the formulation includes hexapropyl-β-cyclodextrin (e.g., in water, 10-50%).

[0549] Indications

[0550] In MTAP-deficient tumors, developing MTA-synergistic PRMT5 inhibitors could provide therapeutic benefits to a large number of cancer patients. The compounds of this invention exert their therapeutic effects by negatively regulating the activity of MTA-bound PRMT5 in tumor cells, particularly against MTAP-deficient cells or various MTAP-associated tumor cells.

[0551] In some embodiments, the MTA-synergistic PRMT5 inhibitors described herein can treat a variety of cancers, including but not limited to tumor types such as malignant peripheral nerve sheath tumor, mesothelioma, glioblastoma multiforme, pancreatic cancer, bile duct cancer, prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, bladder cancer, astrocytoma, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, thymoma, head and neck cancer, hepatocellular carcinoma, laryngeal cancer, squamous cell carcinoma of the lung, lung adenocarcinoma, oral cancer, ovarian cancer, kidney cancer and thyroid cancer, as well as sarcoma.

[0552] More specifically, these compounds can be used to treat: Heart: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma, etc.), myxoma, rhabdomyosarcoma, fibroma, lipoma, and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma, etc.), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondroma, hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma, etc.), stomach (tumor, lymphoma, leiomyosarcoma, etc.), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, hemangioma, etc.), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, etc.), Kaposi's sarcoma, leiomyomas, hemangiomas, lipomas , neurofibroma, fibroma, etc.), colorectal (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma, etc.); genitourinary tract: kidney (adenocarcinoma, Wilms' tumor, etc.), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, etc.), prostate (adenocarcinoma, sarcoma, etc.), testis (seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, lipoma, etc.); liver: hepatoma, bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; bile duct: gallbladder cancer, ampullary carcinoma, bile duct cancer, etc.; bone: osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing sarcoma, malignant lymphoma (reticular cell sarcoma, etc.), Multiple myeloma, malignant giant cell tumor, chordoma, osteochondroma (osteocartilaginous exostosis), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumor of bone; nervous system: skull (osteomas, hemangiomas, granulomas, xanthomas, and osteitis deformans, etc.), meninges (meningiomas, meningiosarcomas, and gliomas, etc.), brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors (pinealomas, etc.), glioblastoma multiforme, oligodendrogliomas, schwannomas, retinoblastomas, and congenital tumors, etc.), spinal neurofibromas, meningiomas, gliomas, and sarcomas, etc.); gynecology: uterus (endometrial cancer, etc.), cervix (cervical cancer, preneoplastic cervical dysplasia, etc.). ), ovary (ovarian cancer, serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma, etc.), granulosa cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma, etc.), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma, etc.), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonic rhabdomyosarcoma, etc.), fallopian tube cancer, etc.; Hematology: blood (myeloid leukemia (acute and chronic), acute lymphocytic leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma (MCL), follicular lymphoma, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome, etc.), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma), etc.;Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, nevus dysplasia, lipoma, hemangioma, dermatofibroma, keloid, psoriasis, etc.; Adrenal gland: neuroblastoma, etc.;

[0553] Combination therapy

[0554] The MTA-synergistic PRMT5 inhibitor of the present invention can be combined with other drugs to treat cancer, including at least one target drug / cell activity regulator, including CDK4 / 6 inhibitors, MAT2A inhibitors, MAPK1 / MAPK3 inhibitors, Type I PRMT inhibitors, EGFR inhibitors, SHP2 inhibitors, pan-KRAS inhibitors, KRASG12C inhibitors, RAF inhibitors, MEK inhibitors, ERK inhibitors, Bcl-2 inhibitors, SOS1 inhibitors, PARP inhibitors, MALT1 inhibitors, MALT2 inhibitors, BTK inhibitors, PI3K inhibitors, AKT inhibitors, FGFR inhibitors, DNA methyltransferase (DNMT) inhibitors, EZH1 / 2 inhibitors, EZH2 inhibitors, Menin-MLL inhibitors, IDH1 inhibitors, IDH2 inhibitors, IDH1 / 2 inhibitors, chemotherapy drugs, radiotherapy, STING agonists or immune checkpoint inhibitors / regulators, etc.

[0555] Example

[0556] The starting materials and reagents used herein are either commercially available or prepared by synthetic methods generally known in the art.

[0557] Example

[0558] 1. Synthesis of Example 1

[0559] 1.1 Synthesis of Intermediate 1-1

[0560] N,O-dimethylhydroxylamine hydrochloride (8.81 g), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (17.3 g) and pyridine (30 mL) were added to a solution of 2-benzyloxyacetic acid (10 g) in dichloromethane (200 mL) and stirred at room temperature for 2 hours. Dilute with dichloromethane (100 mL), wash with 1M hydrochloric acid (100 mL), wash the organic phase with saturated sodium chloride solution (50 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 20 / 1-1 / 1) to give 1-1 as a colorless oil (11 g, yield 78.5%). MS: M+H + =210.

[0561] 1.2 Synthesis of intermediate 1-2

[0562] Under nitrogen protection, n-butyl lithium (2.4M, 21.2mL) was slowly added dropwise to a -78°C tetrahydrofuran (80mL) solution containing 2,2,6,6-tetramethylpiperidine (7.48g). After the addition was complete, the reaction solution was slowly heated to 0°C and then cooled to -78°C. A solution of 6-chloronicotinic acid (2g) in tetrahydrofuran (10mL) was slowly added dropwise to the above reaction solution and stirred at this temperature for 90 minutes. The temperature was raised to -60°C and stirred for 30 minutes. 1-1 (11g) was added at this temperature and then stirred at -30°C to -20°C for 3.5 hours. 10% aqueous citric acid solution was added to quench the mixture and extracted with ethyl acetate (100mL). The organic phase was washed with saturated brine (100mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a pale yellow oily crude product 1-2 (2g), which was used directly in the next step. MS: M+H + =306.

[0563] 1.3 Synthesis of intermediates 1-3

[0564] Trimethylsilyldiazomethane (91.48 g) was added to a solution of 1-2 (2 g) in tetrahydrofuran (20 mL) at 0°C and stirred at room temperature for 2 hours. Water (50 mL) was added to quench the mixture, and the mixture was extracted with ethyl acetate (50 mL). The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 10 / 1-1 / 1) to give 1-3 (680 mg, 30.8% yield) as a white solid. MS: M+H + =320.

[0565] 1.4 Synthesis of Intermediates 1-4

[0566] 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (487 mg), anhydrous sodium carbonate (451 mg), and tetrakis(triphenylphosphine)palladium (247 mg) were added to a solution of 1-3 (680 mg) in dioxane and water (5:1, 8 mL). The mixture was stirred at 100°C under nitrogen for 2 hours. The mixture was cooled to room temperature and concentrated under reduced pressure to obtain a crude brown solid compound 1-4 (1 g), which was used directly in the next reaction. MS: M+H + =352.

[0567] 1.5 Synthesis of intermediate 1-5

[0568] Hydrazine hydrate (1 mL) was added to a solution of 1-4 (1 g) in anhydrous ethanol (10 mL) and stirred at 70°C for 1 hour. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified using a C18 column (acetonitrile / water = 40 / 1 to 1 / 1) to give 1-5 as a white solid (720 mg, yield 71.4%). MS: M+H + =348.

[0569] 1.6 Synthesis of intermediate 1-6

[0570] Boron trichloride (9 mL) was added dropwise to a solution of 1-5 (720 mg) in dichloromethane (7 mL) at -10°C and stirred for 1 hour. An icy saturated aqueous sodium bicarbonate solution (10 mL) was added and stirred at room temperature for 0.5 hour. The mixture was concentrated under reduced pressure and the residue was purified by HPLC (column: Gemini 5u C18 150 x 21.2 mm; mobile phase: [water (FA)-ACN]; B%: 5%-50%, 50 min) to obtain the formate salt of 1-6 as a white solid (300 mg, 56.2% yield). MS: M+H + =258. 1 H NMR(400MHz,DMSO-d6)δppm 12.72(s,1H),9.33(d,J=0.8Hz,1H),8.45(s,1H),8.13(d,J=0.6Hz,1H),8.0 4(d,J=0.9Hz,1H),5.52(t,J=6.1Hz,1H),4.68(d,J=5.9Hz,2H),3.89(s,3H).

[0571] 1.7 Synthesis of Intermediate 1-7

[0572] Diisopropyl azodicarboxylate (313 mg) was added to a solution of 1-6 (200 mg), triphenylphosphine (407 mg), and phthalimide (227 mg) in dichloromethane (3 mL) and stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to obtain a crude white solid compound 1-7 (150 mg), which was used directly in the next reaction. MS: M+H + =387.

[0573] 1.8 Synthesis of Compound 1

[0574] Hydrazine hydrate (3 mL) was added to a solution of crude product 1-7 (150 mg) in anhydrous ethanol (2 mL) and stirred at 70°C for 1 hour. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Gemini 5u C18 150 x 21.2 mm; mobile phase: [water (FA)-ACN]; B%: 5%-50%, 50 min) to obtain the formate salt of 1 as a white solid (3.6 mg, 7.6% yield). MS: M+H+ =257.1. 1 H NMR(400MHz,CD3OD-d4)δppm 9.38(d,J=0.8Hz,1H),8.38(s,1H),8.28(s,1H),8.14(d,J=0.5Hz,1H),7.86(d,J=0.8Hz,1H),4.45(s,2H),3.89(s,3H).

[0575] 2. Synthesis of Example 2

[0576] 2.1 Synthesis of Intermediate 2-1

[0577] Tetrakis(triphenylphosphine)palladium (141 mg), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (507 mg), and potassium carbonate (1.1 g) were added to a mixture of methyl 2,6-dichloronicotinate (500 mg) in tetrahydrofuran (15 mL) and water (3 mL). The mixture was stirred at 80°C for 5 hours under nitrogen. After cooling to room temperature, water (30 mL) was added and the mixture was extracted with ethyl acetate (20 mL*3). The combined organic phases were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1-5 / 1) to obtain compound 2-1 (380 mg, yield 62.3%) as a yellow oil. MS: M+H + =252.0,253.9

[0578] 2.2 Synthesis of intermediate 2-2

[0579] Tributyl(1-ethoxyvinyl)tin (454 mg) and tetrakis(triphenylphosphine)palladium (67.9 mg) were added to a solution of 2-1 (250 mg) in N,N-dimethylformamide (10 mL) and stirred at 100°C for 1 hour under nitrogen. The mixture was cooled to room temperature, added with water (50 mL), and extracted with ethyl acetate (20 mL*3). The combined organic phases were washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 20 / 1-1 / 1) to obtain 2-2 (100 mg, 35% yield) as a white solid. MS: M+H + =288.1.

[0580] 2.3 Synthesis of intermediate 2-3

[0581] N-Bromosuccinimide (74 mg) was added to a solution of 2-2 (100 mg) in tetrahydrofuran (5 mL) and water (0.3 mL) and stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure, ethyl acetate (30 mL) was added, and the mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a yellow solid 2-3 (100 mg), which was used directly in the next reaction. MS: M+H + =338.1,340.0.

[0582] 2.4 Synthesis of Intermediate 2-4

[0583] Sodium azide (24 mg) was added to a solution of 2-3 (100 mg) in N,N-dimethylformamide (10 mL) at 0°C and stirred at 0°C for 30 minutes. Water (50 mL) was added and the mixture was extracted with ethyl acetate (20 mL*3). The combined organic phases were washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, dichloromethane / methanol = 100 / 0–40 / 1) to obtain 2-4 (71 mg, yield 84.3%) as a white solid. MS: M+H + =301.1.

[0584] 2.5 Synthesis of Intermediate 2-5

[0585] Add hydrazine hydrate (135 mg) to a solution of 2-4 (71 mg) in ethanol (5 mL). Stir at 70°C for 3 hours. Cool to room temperature and concentrate under reduced pressure to obtain a yellow solid 2-5 (60 mg), which was used directly in the next reaction. MS: M+H + =283.1.

[0586] 2.6 Synthesis of compound 2

[0587] A mixture of 10% Pd / C (60 mg), 2-5 (60 mg), and methanol (10 mL) was stirred at room temperature under 1 atmosphere of hydrogen for 3 hours. The mixture was filtered under reduced pressure and eluted with hot dimethyl sulfoxide. The filtrate was purified by HPLC (column: Gemini 5u C18 150 x 21.2 mm; mobile phase: ACN-H2O (0.1% FA); B%: 10%-40%; 15 min) to give the formate salt of 2 as an off-white solid (1.7 mg, yield 2.9%). MS: M+H + =257.2, 1 HNMR (400MHz, DMSO-d6) δppm 8.63(d,J=8.5Hz,1H),8.49(s,1H),8.28(s,1H),8.13(d,J=8.5Hz,1H),4.67(s,2H),4.02(s,3H).

[0588] 3. Synthesis of Example 3

[0589] 3.1 Synthesis of Intermediate 3-1

[0590] Tributyl(1-ethoxyvinyl)tin (3.9 g) and bis(triphenylphosphine)palladium dichloride (0.63 g) were added to a solution of ethyl 2,4-dichloropyrimidine-5-carboxylate (2 g) in N,N-dimethylformamide (20 mL) and stirred at 70°C for 2 hours under nitrogen. The reaction mixture was poured into ice-water (100 mL) and extracted with ethyl acetate (50 mL*3). The combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, dichloromethane / methanol = 10 / 1) to obtain 3-1 (1.7 g, 70% yield) as a yellow solid. MS: M+H + =256.9. 1 HNMR(400MHz,CDCl3)δppm 8.70(s,1H),5.38(d,J=2.8Hz,1H),4.61(d,J=2.9Hz,1H),4.36(q,J=7.2H z, 2H), 3.90 (q, J = 7.0Hz, 2H), 1.37 (t, J = 7.2Hz, 3H), 1.33 (t, J = 7.0Hz, 3H).

[0591] 3.2 Synthesis of intermediate 3-2

[0592] 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.47 g), tetrakis(triphenylphosphine)palladium (0.54 g), and potassium carbonate (1.3 g) were added to a solution of 3-1 (1.2 g) in dioxane (10 mL) and water (2.5 mL). The mixture was stirred at 100°C under nitrogen for 2 hours. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 20 / 1 to 3 / 1) to obtain 3-2 (1 g, 65.96% yield) as a yellow solid. MS: M+H + =302.9.

[0593] 3.3 Synthesis of Intermediate 3-3

[0594] N-Bromosuccinimide (453.3 mg) was added to a solution of 3-2 (0.7 g) in tetrahydrofuran (7.5 mL) and water (0.5 mL) and stirred at room temperature for 16 hours. Water (50 mL) was added and extracted with ethyl acetate (50 mL*3). The combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 0-4 / 1) to obtain a yellow solid 3-3 (0.6 g, yield 69.7%). MS: M+H + =352.8,354.7.

[0595] 3.4 Synthesis of Intermediate 3-4

[0596] Sodium azide (82.82 mg) was added to a solution of 3-3 (300 mg) in N,N-dimethylformamide (5 mL) at 0°C and stirred at 0°C for 1 hour. Water (30 mL) was added and the mixture was extracted with ethyl acetate (30 mL*3). The combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a yellow solid 3-4 (200 mg), which was used directly in the next reaction. MS: M+H + =316.0.

[0597] 3.5 Synthesis of intermediate 3-5

[0598] Add hydrazine hydrate (63.51 mg) to a solution of 3-4 (200 mg) in ethanol (5 mL). Stir at 50°C for 3 hours, add water (20 mL), and extract with ethyl acetate (40 mL*3). The organic phase is washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain a yellow solid 3-5 (100 mg), which is used directly in the next reaction. MS: M+H + =284.1.

[0599] 3.6 Synthesis of compound 3

[0600] Triphenylphosphine (37.57 mg) was added to a mixture of 3-5 (50 mg) in tetrahydrofuran (2 mL) and water (0.4 mL), and the mixture was stirred at room temperature for 16 hours. The mixture was concentrated under reduced pressure, and the residue was purified by HPLC (column: -Xbridge-C18 150 x 19 mm, 5 μm; mobile phase: [water (0.05% FA)-ACN]; B%: 2%-20%, 20 min) to obtain the formate salt of 3 as an off-white solid (15 mg, 35% yield). MS: M+H + =258.2. 1H NMR (400MHz, DMSO-d6) δppm 9.54 (s, 1H), 8.62 (s, 1H), 8.20 (d, J = 0.7Hz, 1H), 4.06 (s, 2H), 3.95 (s, 3H).

[0601] 4. Synthesis of Example 4

[0602] 4.1 Synthesis of Intermediate 4-1

[0603] Under nitrogen at 0°C, concentrated sulfuric acid (2.5 mL) was added dropwise to a solution of 3-bromo-5-chloropyridine-2-carboxylic acid (5 g) in methanol (50 mL). The mixture was stirred at 70°C for 16 hours. The mixture was cooled to room temperature and poured into an ice-water mixture (200 mL). The mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine (100 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 4-1 (5 g, 94% yield) as a white solid. MS: M+H + =252.

[0604] 4.2 Synthesis of intermediate 4-2

[0605] Tributyl(1-ethoxyvinyl)tin (1.5 g) and bis(triphenylphosphine)palladium dichloride (0.55 g) were added to a solution of 4-1 (1 g) in N,N-dimethylformamide (10 mL). The mixture was stirred at 100°C for 2 hours under nitrogen. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 1 to 30 / 1) to obtain 4-2 (0.7 g, 73% yield) as a white solid. MS: M+H + =242.

[0606] 4.3 Synthesis of Intermediate 4-3

[0607] N-Bromosuccinimide (391 mg) was added to a mixture of 4-2 (530 mg) in tetrahydrofuran and water (15:1, 10 mL) at room temperature and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure, and ethyl acetate (30 mL) was added to the residue, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 1-4 / 1) to obtain 4-3 (500 mg, 77% yield) as a white solid. MS: M+H + =291.9,294.

[0608] 4.4 Synthesis of Intermediate 4-4

[0609] Under an ice-water bath, trimethylsilyl azide (395 mg) and potassium carbonate (395 mg) were added to a solution of 4-3 (500 mg) in anhydrous acetonitrile (10 mL) and stirred at room temperature for 1 hour. The mixture was filtered under reduced pressure, and the filter cake was rinsed with ethyl acetate (20 mL). The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 1-4 / 1) to obtain 4-4 (260 mg, 59% yield) as a white solid. MS: M+H + =255.

[0610] 4.5 Synthesis of intermediate 4-5

[0611] At room temperature, hydrazine hydrate (102 mg) was added to a solution of 4-4 (260 mg) in ethanol (25 mL) and stirred at 80°C for 2 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, dichloromethane / methanol = 100 / 0 to 100 / 2) to give 4-5 (150 mg, 62% yield) as a white solid. MS: M+H + =237.

[0612] 4.6 Synthesis of Compound 4-6

[0613] Triphenylphosphine (250 mg) and di-tert-butyl dicarbonate (277 mg) were added to a mixture of 4-5 (150 mg) in tetrahydrofuran (6 mL) and water (2 mL) and stirred at 80°C for 1 hour. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, dichloromethane / methanol = 100 / 0 to 100 / 2) to obtain 4-6 (50 mg, 37% yield) as a white solid. MS: M+H + =311.

[0614] 4.7 Synthesis of Compound 4-7

[0615] 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (34 mg), anhydrous potassium carbonate (27 mg), and 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (20 mg) were added to a mixture of 4-6 (40 mg) in dioxane and water (4:1, 2 mL). The mixture was stirred at 100°C under nitrogen for 1 hour. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was added with water (10 mL) and ethyl acetate (10 mL) and filtered under reduced pressure to obtain a gray solid crude product 4-7 (30 mg), which was directly carried out to the next step. MS: M+H + =357.

[0616] 4.8 Synthesis of compound 4

[0617] Trifluoroacetic acid (1 mL) was added to a solution of 4-7 (30 mg) in dichloromethane (3 mL) at 0°C and stirred at 0°C for 1 hour. The mixture was concentrated under reduced pressure, and the residue was purified by HPLC (column: Gemini 5u C18 150 x 21.2 mm; mobile phase: [water (0.1% TFA)-ACN]; B%: 10%-50%, 15 min) to give the trifluoroacetic acid salt of 4 as a white solid (14 mg, 66% yield). MS: M+H + =256.9. 1 H NMR(400MHz,DMSO-d6)δppm 13.09(s,1H),9.39(d,J=2.0Hz,1H),8.58(s,1H),8.48(d,J=2.1Hz,1H),8.42(s,2H),8.28(d,J=0.5Hz,1H),4.50(d,J=5.3Hz,2H),3.94(s,3H).

[0618] 5. Synthesis of Example 5

[0619] 5.1 Synthesis of Intermediate 5-1

[0620] 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.1 g), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (338 mg), and sodium bicarbonate (811 mg) were added to a solution of methyl 4,6-dichloropyridazine-3-carboxylate (1 g) in 1,4-dioxane (15 mL) and water (3 mL). The mixture was stirred at 100°C under nitrogen for 2 hours. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1-5 / 1) to afford 5-1 (500 mg, 41.3% yield) as a yellow solid. MS: M+H + =253.1,255.1

[0621] 5.2 Synthesis of Intermediate 5-2

[0622] Tributyl(1-ethoxyvinyl)tin (1.1 g) and bis(triphenylphosphine)palladium dichloride (139.2 mg) were added to a solution of 5-1 (500 mg) in N,N-dimethylformamide (10 mL) and stirred at 80°C for 1 hour under nitrogen. The mixture was cooled to room temperature, added with water (60 mL), and extracted with ethyl acetate (30 mL*3). The combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 20 / 1-1 / 1) to obtain 5-2 (230 mg, 40.2% yield) as a white solid. MS: M+H + =289.2.

[0623] 5.3 Synthesis of Intermediate 5-3

[0624] N-Bromosuccinimide (62 mg) was added to a solution of 5-2 (100 mg) in tetrahydrofuran (5 mL) and water (0.3 mL). The mixture was stirred at room temperature for 1 hour, concentrated under reduced pressure, and the residue was added with ethyl acetate (60 mL). The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 1-4 / 1) to obtain 5-3 (86 mg, yield 73.5%) as a yellow solid. MS: M+H + =339.1,341.1.

[0625] 5.4 Synthesis of Intermediate 5-4

[0626] Potassium carbonate (70 mg) and trimethylsilyl azide (47 mg) were added to a solution of 5-3 (86 mg) in acetonitrile (5 mL) at 0°C and stirred at 0°C for half an hour. The mixture was filtered under reduced pressure and rinsed with ethyl acetate (20 mL). The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 1-3 / 1) to give 5-4 (30 mg, yield 36.2%) as a white solid. MS: M+H + =302.1.

[0627] 5.5 Synthesis of Intermediate 5-5

[0628] Add hydrazine hydrate (46 mg) to a solution of 5-4 (30 mg) in ethanol (5 mL). Stir at 70°C for 3 hours. Concentrate under reduced pressure to obtain a yellow solid 5-5 (27 mg), which is used directly in the next reaction. MS: M+H + =284.1.

[0629] 5.6 Synthesis of Compound 5

[0630] Triphenylphosphine (60 mg) was added to a solution of 5-5 (27 mg) in tetrahydrofuran (3 mL) and water (1 mL), and the mixture was stirred at 80°C for 5 hours. The mixture was concentrated under reduced pressure, and the residue was purified by HPLC (column: Gemini-C18 150 x 21.2 mm, 5 μm; mobile phase: ACN-H2O (0.1% FA); B%: 2%-10%, 20 min) to give the formate salt of 5 as an off-white solid (5.2 mg, yield 4.1%). MS: M+H + =258.1. 1 H NMR (400MHz, MeOD-d6) δppm 8.52(s,1H),8.30(s,1H),8.25(s,1H),4.58(s,2H),4.00(s,3H).

[0631] 6. Synthesis of Example 6

[0632] 6.1 Synthesis of Intermediate 6-1

[0633] Under nitrogen at -78°C, slowly add 2,2,6,6-tetramethylpiperidine (13.5 g) dropwise to a solution of n-butyllithium (2.4 M, 53 mL) in tetrahydrofuran (100 mL). After completion, slowly warm the mixture to 0°C. Cool the mixture to -78°C and add a solution of 6-chloronicotinic acid (5 g) in tetrahydrofuran (10 mL) dropwise. Stir for 90 minutes. Warm the mixture to -60°C and stir for 30 minutes. Slowly add a solution of N-methoxy-N-methylacetamide (13.1 g) in tetrahydrofuran (20 mL) dropwise. Stir at -30°C to -20°C for 3.5 hours. Quench the mixture with 10% aqueous citric acid (500 mL) and extract with ethyl acetate (100 mL x 3). The combined organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a pale yellow oily crude product 6-1 (7 g), which was used directly in the next reaction. MS: M+H + =199.9.

[0634] 6.2 Synthesis of Intermediate 6-2

[0635] Trimethylsilyldiazomethane (1M, 10 mL) was added to a solution of 6-1 (7 g) in tetrahydrofuran (50 mL) at 0°C and stirred at room temperature for 1 hour. Water (200 mL) was added to quench the mixture and the mixture was extracted with ethyl acetate (50 mL*3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 1-8 / 1) to obtain 6-2 (2.7 g, 40% yield, two steps) as a white solid. MS: M+H + =214.

[0636] 6.3 Synthesis of Intermediate 6-3

[0637] N-iodosuccinimide (3 g) and p-toluenesulfonic acid (0.3 g) were added to a solution of 6-2 (1.8 g) in ethyl acetate (80 mL) and stirred at 80°C for 24 hours. The mixture was cooled to room temperature, washed with water (200 mL), and the aqueous phase was extracted with ethyl acetate (50 mL*3). The combined organic phases were washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 0-10 / 1) to give an off-white solid 6-3 (2.6 g, yield 90%). MS: M+H + =338.

[0638] 6.4 Synthesis of Intermediate 6-4

[0639] Sodium azide (290 mg) was added to a solution of 6-3 (1.5 g) in N,N-dimethylformamide (10 mL) at 0°C and stirred at 0°C for 30 minutes. The mixture was diluted with water (100 mL) and extracted with ethyl acetate (30 mL*3). The combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 0-8 / 1) to give 6-4 (0.7 g, 52% yield) as a white solid. MS: M+H + =299,301.

[0640] 6.5 Synthesis of Intermediate 6-5

[0641] Hydrazine hydrate (128 mg) was added to a solution of 6-4 (0.6 g) in ethanol (5 mL) and stirred at 80°C for 1 hour. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, dichloromethane / methanol = 100 / 0-50 / 1) to give 6-5 as a white solid (0.35 g, yield 62%). MS: M+H + =281,283.

[0642] 6.6 Synthesis of Intermediate 6-6

[0643] Triphenylphosphine (489 mg) and di-tert-butyl dicarbonate (540 mg) were added to a mixture of 6-5 (350 mg) in tetrahydrofuran (15 mL) and water (3 mL), and stirred at 80°C for 1 hour. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, dichloromethane / methanol = 100 / 0-30 / 1) to obtain 6-6 (110 mg, 24% yield) as a white solid. MS: M+H + =355,357.

[0644] 6.7 Synthesis of Intermediate 6-7

[0645] Methyl 2-bromomethylbenzoate (2.36 g) and potassium carbonate (2.84 g) were added to a solution of 1-methyl-5-aminopyrazole (1 g) in N,N-dimethylformamide (10 mL) and stirred at room temperature for 2 hours. Water (200 mL) was added and extracted with ethyl acetate (100 mL*3). The combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 5 / 1-1 / 1) to obtain compound 6-7 (1.3 g, yield 52.4%) as a white solid. MS: M+H + =176.

[0646] 6.8 Synthesis of Intermediate 6-8

[0647] Potassium carbonate (1.69 g) was added to a solution of 6-7 (1.3 g) in N,N-dimethylformamide (15 mL) and stirred at 80°C for 2 hours. The mixture was cooled to room temperature, and water (150 mL) was added. The mixture was extracted with ethyl acetate (100 mL*3). The combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, dichloromethane / methanol = 20 / 1-1 / 1) to give 6-8 (570 mg, 39.3% yield) as a colorless oil. MS: M+H + =214.

[0648] 6.9 Synthesis of Intermediate 6-9

[0649] N-Bromosuccinimide (91.8 mg) was added to a solution of 6-8 (100 mg) in acetonitrile (5 mL) and stirred at 40°C for 2 hours. The mixture was cooled to room temperature, added with water (50 mL), and extracted with ethyl acetate (50 mL*3). The combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 10 / 1-1 / 1) to give 6-9 as a white solid (123 mg, yield: 85.3%). MS: M+H + =292.

[0650] 6.10 Synthesis of Intermediate 6-10

[0651] Under nitrogen at -78°C, n-butyllithium (2.4M, 0.65 mL) was slowly added dropwise to a solution of 6-9 (300 mg) in anhydrous tetrahydrofuran (5 mL). The mixture was stirred at -78°C for 0.5 hours, and tributyltin chloride (1 g) was added dropwise. The temperature was slowly warmed to room temperature and stirred for 2 hours. The mixture was cooled to 0°C and quenched by the addition of saturated aqueous ammonium chloride (1 mL). The mixture was diluted with water (30 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 0-3 / 1) to obtain 6-10 (130 mg, 25% yield) as a yellow liquid. MS: M+H + =504.

[0652] 6.11 Synthesis of Intermediate 6-11

[0653] Add 6-10 (30 mg) and tetrakis(triphenylphosphine)palladium (20 mg) to a solution of 6-6 (100 mg) in N,N-dimethylformamide (1 mL) and stir at 110°C under nitrogen for 4 hours. Cool to room temperature, concentrate under reduced pressure, and purify the residue by thin-layer chromatography (dichloromethane / methanol = 20 / 1) to obtain 6-11 (10 mg, 62.67% yield) as a yellow solid. MS: M+H + =488.

[0654] 6.12 Synthesis of Compound 6

[0655] Trifluoroacetic acid (0.5 mL) was added to a solution of 6-11 (10 mg) in dichloromethane (1 mL) at 0°C and stirred at 0°C for 1 hour. The mixture was concentrated under reduced pressure, and the residue was purified by HPLC (column: AZZOTA C18 100A 10 μm; mobile phase: [water (0.1% NH3)-ACN]; B%: 10%-35%, 17 min) to give 6 (1.5 mg, 18% yield) as a white solid. MS: M+H + =388.2. 1 HNMR(400MHz,MeOD-d4)δppm 9.16(s,1H),8.39(s,1H),7.94(s,1H),7.90(d,J=7.7Hz,1H),7.80-7.76(m, 1H),7.70(d,J=7.8Hz,1H),7.62(t,J=7.3Hz,1H),4.24(s,2H),3.86(s,3H).

[0656] 7. Synthesis of Example 7

[0657] 7.1 Synthesis of Compound 7

[0658] A mixture of 10% palladium on carbon (18.78 mg), 3-5 (50 mg), and methanol (5 mL) was stirred at room temperature under 1 atmosphere of hydrogen for 16 hours. The mixture was concentrated under reduced pressure, dissolved in thionyl chloride with heat, filtered, and the organic phase was purified by HPLC (column: Gemini-C18 150 x 21.2 mm, 5 μm; mobile phase: [H2O (0.1% TFA)-ACN]; B%: 2%-100%, 20 min) to afford the trifluoroacetic acid salt of 7 as an off-white solid (20 mg, 40% yield). LC-MS m / z (ESI): 260.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δppm 12.76 (s, 1H), 8.66 (s, 1H), 8.29 (s, 1H), 8.14 (s, 3H), 7.99 (s, 1H), 4.38 (s, 2H), 4.03 (d, J = 5.5Hz, 2H), 3.89 (s, 3H).

[0659] 8. Synthesis of Example 8

[0660] 8.1 Synthesis of Intermediate 8-1

[0661] At -78°C, n-butyllithium (2.8 mL, 1 M) was slowly added dropwise to a solution of 5-bromo-3-methylisothiazole (1.0 g) in tetrahydrofuran (50 mL). The temperature was maintained below -70°C and stirred for 10 minutes. A solution of tributyltin chloride (2.4 g) in tetrahydrofuran (10 mL) was slowly added to the reaction mixture, and the temperature was maintained below -70°C and stirred for 2 hours. The mixture was warmed to 0°C and quenched by the addition of saturated ammonium chloride solution (5 mL). Water (100 mL) was added and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phase was washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 8-1 (1.6 g, 66.0% yield) as a yellow oil.

[0662] 8.2 Synthesis of Intermediate 8-2

[0663] Methyl 2,6-dichloronicotinate (724.0 mg) and bis(triphenylphosphine)palladium dichloride (235.0 mg) were added to a solution of compound 8-1 (1.3 g) in N,N-dimethylformamide (15 mL) and stirred at 80°C for 2 hours. After cooling to room temperature, water (100 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain 8-2 (550.0 mg, 57.0% yield) as a yellow solid. LC-MS m / z (ESI): 269.0 [M+H] + .

[0664] 8.3 Synthesis of Intermediate 8-3

[0665] Tributyl(1-ethoxyethylene)tin (961.0 mg) and tetrakis(triphenylphosphine)palladium (236.0 mg) were added to a solution of compound 8-2 (550.0 mg) in N,N-dimethylformamide (15 mL) and stirred at 100°C for 2 hours. After cooling to room temperature, water (100 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 8-3 as a yellow solid (500.0 mg, yield 80.0%). LC-MS m / z (ESI): 305.1 [M+H] + .

[0666] 8.4 Synthesis of Intermediate 8-4

[0667] N-Bromosuccinimide (351.0 mg) was added to a mixture of compound 8-3 (500.0 mg) in tetrahydrofuran and water (10 mL, V / V = 15:1) and stirred at room temperature for 30 minutes. Water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain a yellow solid 8-4 (510.0 mg, yield 87.0%). LC-MS m / z (ESI): 354.9 [M+H] + .

[0668] 8.5 Synthesis of Intermediate 8-5

[0669] Azidotrimethylsilane (324.0 mg) and potassium carbonate (389.0 mg) were added to a solution of compound 8-4 (200.0 mg) in acetonitrile (20 mL) and stirred at 40°C for 16 hours. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain a yellow solid 8-5 (120.0 mg, yield 67.0%). LC-MS m / z (ESI): 318.9 [M+H] + .

[0670] 8.6 Synthesis of Intermediate 8-6

[0671] Hydrazine hydrate (15.0 mg) was added to a solution of compound 8-5 (120.0 mg) in ethanol (5 mL) and stirred at 70°C for 3 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to obtain a white solid 8-6 (70.0 mg, yield 75.0%). LC-MS m / z (ESI): 300.0 [M+H] + .

[0672] 8.7 Synthesis of Compound 8

[0673] Triphenylphosphine (88.0 mg) was added to a mixture of compound 8-6 (70.0 mg) in tetrahydrofuran and water (5 mL, V / V = 5:1) and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. The residue was purified by HPLC (column: Gemini 5u C18 150 x 21.2 mm; mobile phase: ACN-H2O (0.05% NH4OH); B%: 2%-10%, 11 min) to afford 8 (23.8 mg, 43.0% yield) as a white solid. LC-MS m / z (ESI): 274.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δppm 8.71 (d, J = 8.4Hz, 1H), 8.40 (d, J = 8.4Hz, 1H), 8.28 (s, 1H), 8.10 (s, 1H), 4.19 (s, 2H), 2.52 (s, 3H).

[0674] 9. Synthesis of Example 9

[0675] 9.1 Synthesis of Intermediate 9-1

[0676] Tributyl(1-ethoxyethylene)tin (3.9 g) and bistriphenylphosphine palladium dichloride (0.6 g) were added to a solution of ethyl 2,4-dichloro-5-pyrimidinecarboxylate (2.0 g) in N,N-dimethylformamide (20 mL) and stirred at 70°C for 16 hours. The reaction mixture was poured into ice water (100 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 0-10 / 1) to obtain 9-1 (1.7 g, 70% yield) as a yellow solid. LC-MS m / z (ESI): 256.9 [M+H] + . 1 H NMR (400MHz, CDCl3) δppm 8.70(s,1H),5.38(d,J=2.8Hz,1H),4.61(d,J=2.9Hz,1H),4.36(q,J=7.2H z, 2H), 3.90 (q, J = 7.0Hz, 2H), 1.37 (t, J = 7.2Hz, 3H), 1.33 (t, J = 7.0Hz, 3H).

[0677] 9.2 Synthesis of Intermediate 9-2

[0678] 6-9 (0.6 g), palladium acetate (46.0 mg), 2-dicyclohexylphosphino-2,6-dimethoxy-biphenyl (168.0 mg), and triethylamine (1.0 g) were added to a dioxane (10 mL) solution, and pinacol borane (1.0 g) was slowly added at room temperature. Stir at 70°C for 2 hours under nitrogen. Cool to room temperature, add water (30 mL), and extract with ethyl acetate (20 mL x 3). The organic phase was washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to obtain 9-2 (0.3 g, 43.0% yield) as a yellow solid. LC-MS m / z (ESI): 340.1 [M+H] + .

[0679] 9.3 Synthesis of Intermediate 9-3

[0680] 9-1 (200.0 mg), tetrakistriphenylphosphine palladium (84.0 mg), and sodium carbonate (155.0 mg) were added to a solution of 9-2 (298.0 mg) in dioxane (4 mL) and water (1 mL). The mixture was stirred at 100°C under nitrogen for 2 hours. After cooling to room temperature, water (15 mL) was added and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phase was washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain 9-3 (190.0 mg, yield 60.0%) as a brown oil. LC-MS m / z (ESI): 434.2 [M+H] + .

[0681] 9.4 Synthesis of Intermediate 9-4

[0682] N-Bromosuccinimide (85.0 mg) was added to a solution of 9-3 (190.0 mg) in tetrahydrofuran (3 mL) and water (1 mL) and stirred at room temperature for 1 hour. Water (10 mL) was added and the mixture was extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to obtain 9-4 (150.0 mg, yield 64.0%) as a yellow solid. LC-MS m / z (ESI): 483.9, 485.9 [M+H] + .

[0683] 9.5 Synthesis of Intermediate 9-5

[0684] Azidotrimethylsilane (71.4 mg) was added to a solution of potassium carbonate (150.0 mg) and 9-4 (150.0 mg) in acetonitrile (2 mL) at 0°C and stirred at 0°C for 1 hour. The mixture was warmed to room temperature, filtered, and the filtrate was concentrated under reduced pressure to afford 9-5 (70.0 mg) as a white solid. The crude product was used directly in the next reaction without purification. LC-MS m / z (ESI): 447.1 [M+H] + .

[0685] 9.6 Synthesis of Intermediate 9-6

[0686] Hydrazine hydrate (34.0 mg) was added to a solution of 9-5 (70.0 mg) in ethanol (2 mL). The mixture was stirred at room temperature for 2 hours, and water (8 mL) was added. The mixture was filtered to obtain a white solid 9-6 (50.0 mg). The crude product was used directly in the next step without purification. LC-MS m / z (ESI): 415.1 [M+H] + .

[0687] 9.7 Synthesis of Compound 9

[0688] Triphenylphosphine (63.3 mg) was added to a solution of 9-6 (50.0 mg) in tetrahydrofuran (1.5 mL) and water (0.3 mL), and the mixture was stirred at 50°C for 2 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by HPLC (column: -Xbridge-C18 150 x 19 mm, 5 μm; mobile phase: [H2O(0.05% NH3)-ACN]; B%: 2%-20%, 20 min) to afford 9 (11.0 mg, 35.1% yield) as a white solid. LC-MS m / z (ESI): 389.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δppm 9.49(s,1H),8.38(s,1H),7.87(d,J=8Hz,1H),7.81-7.74(m,2H),7.63(t ,J=8Hz,1H),5.15(s,1H),4.96(s,1H),3.83(s,3H),3.27(d,J=8Hz,2H).

[0689] 10. Synthesis of Example 10

[0690] 10.1 Synthesis of Intermediate 10-1

[0691] Methyl 2-bromomethylbenzoate (1.5 g) and potassium carbonate (3.0 g) were added to a solution of 3-methyliso-4-aminothiazole hydrochloride (1.0 g) in N,N-dimethylformamide (20 mL) and stirred at 80°C for 5 hours. The mixture was cooled to room temperature, and water (50 mL) was added. The mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to obtain 10-1 (1.3 g, 81.1% yield) as a white solid. LC-MS m / z (ESI): 231.1 [M+H] + .

[0692] 10.2 Synthesis of Intermediate 10-2

[0693] At -78°C, n-butyllithium (1.8 mL, 2.5 M) was slowly added dropwise to a tetrahydrofuran solution (20 mL) of 10-1 (1.0 g). The temperature was kept below -70°C and stirred for 10 minutes. A tetrahydrofuran solution (10 mL) of tributyltin chloride (2.1 g) was slowly added to the reaction solution and stirred for 2 hours at a temperature below -70°C. The mixture was heated to 0°C and quenched by the addition of saturated ammonium chloride solution (5 mL). Water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 10-2 (800.0 mg, yield 38.2%) as a white solid. LC-MS m / z (ESI): 520.9 [M+H] + .

[0694] 10.3 Synthesis of Intermediate 10-3

[0695] Tributyl(1-ethoxyethylene)tin (2.0 g) and bis(triphenylphosphine)palladium dichloride (200.0 mg) were added to a solution of ethyl 2,4-dichloro-5-pyrimidinecarboxylate (1.0 g) in N,N-dimethylformamide (30 mL) and stirred at 80°C for 2 hours. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 8 / 1) to obtain 10-3 as a yellow solid (400.0 mg, yield 34.1%). LC-MS m / z (ESI): 257.1 [M+H] + .

[0696] 10.4 Synthesis of Intermediate 10-4

[0697] Compound 10-2 (600.0 mg) and dichloro[1,1'-bis(tert-butylphosphino)ferrocenepalladium(II)] (100.0 mg) were added to compound 10-3 (400.0 mg) in N,N-dimethylformamide (10 mL) and stirred at 100°C for 2 hours. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to obtain a yellow solid 10-4 (110.0 mg, yield 16.1%). LC-MS m / z (ESI): 451.1 [M+H] + .

[0698] 10.5 Synthesis of Intermediate 10-5

[0699] N-Bromosuccinimide (80.0 mg) was added to a mixture of tetrahydrofuran and water (5 mL, V / V = 15:1) of compound 10-4 (100.0 mg) and stirred at room temperature for 30 minutes. Water (20 mL) was added and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phase was washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to obtain a yellow solid 10-5 (100.0 mg, yield 90.2%). LC-MS m / z (ESI): 501.0, 503.0 [M+H] + .

[0700] 10.6 Synthesis of Intermediate 10-6

[0701] Azidotrimethylsilane (100.0 mg) and potassium carbonate (50.0 mg) were added to a solution of compound 10-5 (100.0 mg) in acetonitrile (5 mL) and stirred at 40°C for 16 hours. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to afford 10-6 (50.0 mg, 54.2% yield) as a yellow solid. LC-MS m / z (ESI): 463.9 [M+H] + .

[0702] 10.7 Synthesis of Intermediate 10-7

[0703] Hydrazine hydrate (50.0 mg) was added to a solution of compound 10-6 (50.0 mg) in ethanol (5 mL) and stirred at 70°C for 3 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to obtain 10-7 (25.0 mg, 54.2% yield) as a white solid. LC-MS m / z (ESI): 431.9 [M+H] + .

[0704] 10.8 Synthesis of Compound 10

[0705] Triphenylphosphine (30.0 mg) was added to a mixture of tetrahydrofuran and water (5 mL, V / V = 5:1) of compound 10-7 (25.0 mg) and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. The residue was purified by preparative high-pressure liquid chromatography (HPLC) (column: Gemini 5u C18 150 x 21.2 mm; mobile phase: ACN-H2O (0.05% TFA); B%: 5%-45%, 30 min) to afford the trifluoroacetate salt of compound 10 (1.4 mg, 6.4% yield) as a white solid. LC-MS m / z (ESI): 406.1 [M+H] + . 1 H NMR(400MHz,MeOD-d4)δppm 9.53(s,1H),7.83(d,J=7.6Hz,1H),7.73-7.68(m,1H),7.63(d,J=7.6Hz,1H),7.57(t,J=7.2Hz,1H),4.51(s,2H),3.75(s,2H),2.38(s,3H).

[0706] 11. Synthesis of Example 11

[0707] 11.1 Synthesis of Intermediate 11-1

[0708] Isoindolin-1-one (1.0 g), tris-(diphenylene-base acetone)dipalladium (344.0 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (435.0 mg), and cesium carbonate (7.0 g) were added to a solution of 3-bromo-4-iodopyridine (3.0 g) in 1,4-dioxane (30 mL). The mixture was stirred at 70°C under nitrogen for 16 hours. After cooling to room temperature, water (30 mL) was added and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1 to 1 / 1) to obtain 11-1 (600.0 mg, 27.6% yield) as a yellow solid. LC-MS m / z(ESI):288.9,290.9[M+H] + .

[0709] 11.2 Synthesis of Intermediate 11-2

[0710] Hexabutylditin (12.3 g), tricyclohexylphosphine (0.8 g), lithium chloride (3.0 g), and tris(dibenzylideneacetone)dipalladium (1.3 g) were added to a solution of compound 6-6 (5.0 g) in 1,4-dioxane (20 mL) and stirred at 100°C for 16 hours. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain a yellow oil 11-2 (4.5 g, yield 71.4%). LC-MS m / z (ESI): 467.2 [M+H] + .

[0711] 11.3 Synthesis of Intermediate 11-3

[0712] 11-2 (306.0 mg) and tetrakistriphenylphosphine palladium (50.0 mg) were added to a solution of 11-1 (500.0 mg) in N,N-dimethylformamide (10 mL) and stirred at 110°C for 16 hours. The mixture was cooled to room temperature, added with water (10 mL), and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 20 / 1) to obtain 11-3 (100.0 mg, yield 59.5%) as a yellow solid. LC-MS m / z (ESI): 485.0 [M+H] + .

[0713] 11.4 Synthesis of Compound 11

[0714] Under ice, trifluoroacetic acid (1 mL) was added to a solution of 11-3 (100.0 mg) in dichloromethane (2 mL). The mixture was stirred at room temperature for 1 hour, adjusted to pH 8 with saturated sodium carbonate solution, extracted with dichloromethane (10 mL x 3), and concentrated under reduced pressure. The residue was purified by HPLC (column: Xbridge-C18 150 x 19 mm, 5 μm; mobile phase: ACN-H2O (0.1% FA); B%: 5%-10%, 20 min) to afford the formate salt of 11 (35.0 mg, 44.3% yield) as a white solid. LC-MS m / z (ESI): 385.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δppm12.76(s,1H),9.26(s,1H),9.00(s,1H),8.80(d,J=5.6Hz,1H),8.16(s,1H),7 .79(d,J=5.6Hz,1H),7.67-7.66(m,2H),7.56–7.55(m,1H),7.49-7.44(m,1H),5.10(s,2H),3.80(s,2H).

[0715] 12. Synthesis of Example 12

[0716] 12.1 Synthesis of Intermediate 12-1

[0717] Methyl 2,6-dichloronicotinate (400.0 mg), potassium carbonate (538.0 mg), and tetrakis(triphenylphosphine)palladium (200.0 mg) were added to a mixture of 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.3 g) in tetrahydrofuran (10 mL) and water (10 mL). The mixture was stirred at 80°C for 3 hours under nitrogen. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 50 / 1) to obtain 12-1 (400.0 mg, 81.6% yield) as a yellow solid. LC-MS m / z(ESI):251.9[M+H] + .

[0718] 12.2 Synthesis of Intermediate 12-2

[0719] Tributyl(1-ethoxyethylene)tin (1.2 g) and tetrakis(triphenylphosphine)palladium (200.0 mg) were added to a solution of compound 12-1 (400.0 mg) in N,N-dimethylformamide (5 mL) and stirred at 100°C for 2 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was washed with diethyl ether (30 mL) to obtain a black oil 12-2 (600.0 mg). The crude product was used directly in the next reaction. LC-MS m / z (ESI): 288.2 [M+H] + .

[0720] 12.3 Synthesis of Intermediate 12-3

[0721] N-Bromosuccinimide (356.0 mg) was added to a mixture of compound 12-2 (600.0 mg) in tetrahydrofuran and water (10 mL, V / V = 15:1) and stirred at room temperature for 30 minutes. Water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain 12-3 as a white solid (270.0 mg, two-step yield 48.4%). LC-MS m / z (ESI): 337.9, 339.9 [M+H] + .

[0722] 12.4 Synthesis of Intermediate 12-4

[0723] Under an ice-bath nitrogen atmosphere, trimethylsilyl azide (177.0 mg) and potassium carbonate (212.0 mg) were added to a solution of compound 12-3 (260.0 mg) in anhydrous acetonitrile (20 mL) and stirred at 40°C for 16 hours. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to afford compound 12-4 (130.0 mg, 56.5% yield) as a white solid. LC-MS m / z (ESI): 301.1 [M+H] + .

[0724] 12.5 Synthesis of Intermediate 12-5

[0725] Hydrazine hydrate (50.0 mg) was added to a solution of compound 12-4 (130.0 mg) in ethanol (5 mL) and stirred at 70°C for 1 hour. The mixture was cooled to room temperature, filtered under reduced pressure, and dried to obtain a white solid 12-5 (100.0 mg). The crude product was used directly in the next reaction. LC-MS m / z (ESI): 283.1 [M+H] + .

[0726] 12.6 Synthesis of Compound 12

[0727] Triphenylphosphine (150.0 mg) was added to a mixture of compound 12-5 (100.0 mg) in tetrahydrofuran and water (5 mL, V / V = 3:1) and stirred at room temperature for 5 hours. Diethyl ether (30 mL) was added and the mixture was filtered under reduced pressure. The filter cake was rinsed with ethyl acetate (10 mL) and diethyl ether (10 mL) and dried to obtain 12 (46.5 mg, 46.8% yield) as a white solid. LC-MS m / z (ESI): 257.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δppm 13.11 (s, 1H), 8.56 (d, J = 8.0Hz, 1H), 8.30 (d, J = 8.0Hz, 1H), 6.80 (s, 1H), 4.08 (s, 2H), 2.32 (s, 3H).

[0728] 13. Synthesis of Example 13

[0729] 13.1 Synthesis of Intermediate 13-1

[0730] Methyl 2,6-dichloronicotinate (700.0 mg) and bis(triphenylphosphine)palladium dichloride (200.0 mg) were added to a solution of compound 10-2 (800.0 mg) in N,N-dimethylformamide (15 mL) and stirred at 80°C for 2 hours. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to obtain 13-1 (300.0 mg, yield 49.1%) as a yellow solid. LC-MS m / z (ESI): 400.0 [M+H] + .

[0731] 13.2 Synthesis of Intermediate 13-2

[0732] Tributyl(1-ethoxyethylene)tin (500.0 mg) and tetrakis(triphenylphosphine)palladium (120.0 mg) were added to compound 13-1 (300.0 mg) in N,N-dimethylformamide (10 mL) and stirred at 100°C for 2 hours. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 13-2 as a yellow solid (300.0 mg, yield 92.1%). LC-MS m / z (ESI): 436.2 [M+H] + .

[0733] 13.3 Synthesis of Intermediate 13-3

[0734] N-Bromosuccinimide (200.0 mg) was added to a mixture of tetrahydrofuran and water (10 mL, V / V = 15:1) of compound 13-2 (300.0 mg) and stirred at room temperature for 30 minutes. Water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain 13-3 as a yellow solid (200.0 mg, yield 60.3%). LC-MS m / z (ESI): 485.9, 487.8 [M+H] + .

[0735] 13.4 Synthesis of Intermediate 13-4

[0736] Azidotrimethylsilane (324.0 mg) and potassium carbonate (389.0 mg) were added to a solution of compound 13-3 (200.0 mg) in acetonitrile (10 mL) and stirred at 40°C for 16 hours. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to afford 13-4 (100.0 mg, 54.1% yield) as a yellow solid. LC-MS m / z (ESI): 448.9 [M+H] + .

[0737] 13.5 Synthesis of Intermediate 13-5

[0738] Hydrazine hydrate (150.0 mg) was added to a solution of compound 13-4 (100.0 mg) in ethanol (5 mL) and stirred at 70°C for 3 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to afford compound 13-5 (80.0 mg, yield 84.1%) as a white solid. LC-MS m / z (ESI): 300.0 [M+H] + .

[0739] 13.6 Synthesis of Compound 13

[0740] Triphenylphosphine (80.0 mg) was added to a mixture of tetrahydrofuran and water (5 mL, V / V = 5:1) of compound 13-5 (80.0 mg) and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. The residue was purified by high-pressure liquid chromatography (column: Gemini 5u C18 150 x 21.2 mm; mobile phase: ACN-H2O (0.05% TFA); B%: 5%-45%, 30 min) to obtain the trifluoroacetate salt of 13 as a white solid (15.0 mg, 21% yield). LC-MS m / z (ESI): 405.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δppm 13.23(s,1H),8.67(d,J=8.4Hz,1H),8.33(s,2H),7.86-7.82(m,2H),7.80- 7.69(m,2H),7.62(t,J=7.6Hz,1H),4.91(s,2H),4.32(s,2H),2.37(s,3H).

[0741] 14. Synthesis of Example 14

[0742] 14.1 Synthesis of Intermediate 14-1

[0743] Tributyl(1-ethoxyethylene)tin (16.0 g) and bis(triphenylphosphine)palladium dichloride (3.1 g) were added to a solution of methyl 2-chloro-6-methoxynicotinic acid (8.0 g) in N,N-dimethylformamide (200 mL) and stirred at 100°C for 5 hours. After cooling to room temperature, water (200 mL) was added and the mixture was extracted with ethyl acetate (200 mL x 3). The organic phase was washed with saturated sodium chloride solution (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to obtain 14-1 (8.0 g, yield 85.1%) as a colorless liquid. LC-MS m / z (ESI): 238.2 [M+H] + .

[0744] 14.2 Synthesis of Intermediate 14-2

[0745] N-Bromosuccinimide (9.0 g) was added to a mixture of tetrahydrofuran and water (100 mL, V / V = 15:1) of compound 14-1 (8.0 g) and stirred at room temperature for 30 minutes. Water (100 mL) was added and the mixture was extracted with ethyl acetate (100 mL × 3). The organic phase was washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 8 / 1) to obtain a white solid 14-2 (8.4 g, yield 87.1%). LC-MS m / z (ESI): 288.0, 290.0 [M+H] + .

[0746] 14.3 Synthesis of Intermediate 14-3

[0747] Azidotrimethylsilane (10.0 g) and potassium carbonate (7.0 g) were added to a solution of compound 14-2 (8.3 g) in acetonitrile (100 mL) and stirred at 40°C for 5 hours. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 8 / 1) to obtain a yellow solid 14-3 (6.5 g, yield 89.1%). LC-MS m / z (ESI): 251.1 [M+H] + .

[0748] 14.4 Synthesis of Intermediate 14-4

[0749] Hydrazine hydrate (6.5 g) was added to a solution of compound 14-3 (6.5 g) in ethanol (100 mL) and stirred at 70°C for 3 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to obtain compound 14-4 (5.8 g, yield 86.3%) as a white solid. LC-MS m / z (ESI): 233.1 [M+H] + .

[0750] 14.5 Synthesis of Intermediate 14-5

[0751] Sodium hydride (900.0 mg, 60%) and 2-(trimethylsilyl)ethoxymethyl chloride (8.0 g) were added sequentially to a solution of compound 14-4 (5.5 g) in N,N-dimethylformamide (50 mL) at 0°C and stirred at 0°C for 1 hour. Water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 14-5 (4.5 g, 52.1% yield) as a yellow solid. LC-MS m / z (ESI): 385.1 [M+Na] + .

[0752] 14.6 Synthesis of Intermediate 14-6

[0753] Triphenylphosphine (3.5 g) was added to a mixture of compound 14-5 (4.5 g) in tetrahydrofuran and water (50 mL, V / V = 5:1) and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. Di-tert-butyl dicarbonate (5.0 g) was then added to the tetrahydrofuran solution of the crude product and stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain a white solid 14-6 (3.0 g, yield 55.1%). LC-MS m / z (ESI): 459.2 [M+Na] + .

[0754] 14.7 Synthesis of Intermediate 14-7

[0755] Lithium iodide (1.0 g) was added to a solution of compound 14-6 (1.0 g) in N,N-dimethylformamide (10 mL) and stirred at 150°C for 4 hours. The mixture was cooled to room temperature, and water (50 mL) was added. The mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain a yellow solid 14-7 (480.0 mg, yield 46.2%). LC-MS m / z (ESI): 445.2 [M+Na] + .

[0756] 14.8 Synthesis of Intermediate 14-8

[0757] Pyridine (50.0 mg) and trifluoromethanesulfonic anhydride (200.0 mg) were added to a solution of compound 14-7 (220.0 mg) in dichloromethane (5 mL) at 0°C and stirred at 0°C for 2 hours. Water (10 mL) was added and the mixture was extracted with dichloromethane (10 mL x 3). The organic phase was washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 14-8 (180.0 mg, yield 62.2%) as a white solid. LC-MS m / z (ESI): 577.0 [M+Na] + .

[0758] 14.9 Synthesis of Intermediate 14-9

[0759] Methyl 2-(2-bromoethyl)benzoate (1.0 g) and potassium carbonate (1.5 g) were added to a solution of 3-methyl-4-aminoisothiazole hydrochloride (500 mg) in N,N-dimethylformamide (20 mL) and stirred at 80°C for 5 hours. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to obtain 14-9 as a white solid (600.0 mg, yield 71.2%). LC-MS m / z (ESI): [M+H] + .

[0760] 14.10 Synthesis of Intermediate 14-10

[0761] At -78°C, n-butyllithium (0.4 mL, 2.5 M) was slowly added dropwise to a tetrahydrofuran solution (20 mL) of 14-9 (200.0 mg), and the temperature was kept below -70°C and stirred for 10 minutes. A tetrahydrofuran solution (2 mL) of tributyltin chloride (500.0 mg) was slowly added to the reaction solution, and the temperature was kept below -70°C and stirred for 2 hours. The mixture was heated to 0°C and quenched by the addition of saturated ammonium chloride solution (2 mL). Water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 14-10 (100.0 mg, yield 23.2%) as a white solid. LC-MS m / z (ESI): 535.0 [M+H] + .

[0762] 14.11 Synthesis of Intermediate 14-11

[0763] Compound 14-8 (100.0 mg) and methanesulfonic acid [n-butyldi(1-adamantyl)phosphine] (2-amino-1,1'-biphenyl-2-yl) palladium (II) (20.0 mg) were added to a solution of compound 14-10 (90.0 mg) in N,N-dimethylformamide (2 mL) and stirred at 80°C for 2 hours. After cooling to room temperature, ethyl acetate (30 mL) was added and the mixture was extracted with water (20 mL x 3). The organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 30 / 1) to obtain 14-11 (60.0 mg, 57% yield) as a white solid. LC-MS m / z (ESI): 649.2 [M+H] + .

[0764] LC-MS m / z(ESI):385.1[M+Na] + .

[0765] 14.12 Synthesis of Compound 14

[0766] A mixture of compound 14-11 (60.0 mg) in dichloromethane and trifluoroacetic acid (3 mL, V / V = 5:1) was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. Aqueous ammonia (1 mL) was added to a solution of the crude product in dioxane (3 mL), stirred at 50°C for 2 hours, and the reaction solution was concentrated under reduced pressure. The residue was purified by high-pressure liquid chromatography (column: Gemini 5u C18 150 x 21.2 mm; mobile phase: ACN-H2O (0.05% TFA); B%: 5%-50%, 30 min) to obtain the trifluoroacetic acid salt of 14 as a white solid (4.1 mg, 11.2% yield). LC-MS m / z (ESI): 419.0 [M+H] + . 1 H NMR(400MHz,MeOD-d4)δppm 8.57(d,J=8.4Hz,1H),8.32(d,J=7.6Hz,1H),8.25(d,J=8.4Hz,1H),7.54-7.49(m,1H),7.42(t,J=7.2 Hz,1H),7.31(d,J=7.6Hz,1H),4.53(s,2H),4.29(t,J=6.0Hz,2H),3.00(t,J=5.8Hz,2H),2.24(s,3H).

[0767] The following compounds were synthesized by the same synthesis strategy as in Example 11 or 14:

[0768] Experimental Example 1: Determination of PRMT5:MEP50 enzyme inhibitory activity of the compounds of the present invention using radioisotope Flash Plate technology in the presence of MTA

[0769] (1) Prepare 1× reaction buffer (50 mM Tris 8.0 (Sigma, Cat. No. 93362), 0.01% Tween-20 (Sigma, Cat. No. P9416), 1 mM DTT (Sigma, Cat. No. D9779), 50 mM NaCl (Sigma, Cat. No. S9888).

[0770] (2) The test compound and positive control compound were tested starting at 10 μM and diluted 3-fold to 10 concentrations. The test compound and positive control were diluted with DMSO to 100× the test concentration (i.e., 1 mM). The test compound was then diluted 3-fold to 10 concentrations. Next, the test compound was diluted 20-fold with 1× reaction solution (DMSO concentration was 5%). Finally, 5 μL of each was added to a 384-well reaction plate for testing. Each compound was tested in duplicate. 5 μL of 5% DMSO was transferred to the Max well and Min well.

[0771] (3) Prepare an enzyme solution with a final concentration of 2.5 times using 1× reaction buffer.

[0772] (4) Add 10 μL of enzyme solution at 2.5 times the final concentration to the compound wells and positive control wells respectively; add 10 μL of 1× reaction buffer to the negative control wells.

[0773] (5) Centrifuge at 1000 rpm for 60 seconds, shake to mix, and incubate at room temperature for 15 minutes.

[0774] (6) Prepare 2.5 times the final concentration of 3 A mixed solution of H-SAM, H4 peptide, and MTA.

[0775] (7) Add 10 μL of the mixed solution of step (6) at 2.5 times the final concentration to start the reaction.

[0776] (8) Centrifuge the 384-well plate at 1000 rpm for 60 seconds, shake to mix, and incubate at room temperature for 60 minutes.

[0777] (9) Prepare stop solution (200 μM SAM (Sigma, Cat. No. A7007)) with 1× reaction buffer.

[0778] (10) Add 5 μL of stop solution, centrifuge at 1000 rpm for 60 seconds, transfer all the solutions in each well to FlashPlate, and incubate at room temperature for 60 minutes.

[0779] (11) Readings were made using MicroBeta2.

[0780] (12) Calculation formula

[0781] Inhibition%=100-(RLU-Mean(NC)) / (Mean(PC)-Mean(NC))*100

[0782] RLU: Luminescence value of the sample;

[0783] Mean (NC): average luminescence value of negative control;

[0784] Mean (PC): average luminescence value of positive control;

[0785] Dose-effect curves were fitted using GraphPad Prism 5 software, and IC50 was calculated using the 'log[inhibitor] vs. response-variable slope' procedure.

[0786] Experimental Example 2: Determination of PRMT5:MEP50 enzyme inhibitory activity of the compounds of the present invention using radioisotope flash plate technology in the absence of MTA

[0787] (1) Prepare 1× reaction buffer (50 mM Tris 8.0 (Sigma, Cat. No. 93362), 0.01% Tween-20 (Sigma, Cat. No. P9416), 1 mM DTT (Sigma, Cat. No. D9779), 50 mM NaCl (Sigma, Cat. No. S9888).

[0788] (2) The test compound and positive control compound were tested starting at 10 μM and diluted 3-fold to 10 concentrations. The test compound and positive control were diluted with DMSO to 100× the test concentration (i.e., 1 mM). The test compound was then diluted 3-fold to 10 concentrations. Next, the test compound was diluted 20-fold with 1× reaction solution (DMSO concentration was 5%). Finally, 5 μL of each was added to a 384-well reaction plate for testing. Each compound was tested in duplicate. 5 μL of 5% DMSO was transferred to the Max well and Min well.

[0789] (3) Prepare an enzyme solution with a final concentration of 2.5 times using 1× reaction buffer.

[0790] (4) Add 10 μL of enzyme solution at 2.5 times the final concentration to the compound wells and positive control wells respectively; add 10 μL of 1× reaction buffer to the negative control wells.

[0791] (5) Centrifuge at 1000 rpm for 60 seconds, shake to mix, and incubate at room temperature for 15 minutes.

[0792] (6) Prepare 2.5 times the final concentration of 3 Mixed solution of H-SAM and H4 peptide.

[0793] (7) Add 10 μL of the mixed solution of step (6) at 2.5 times the final concentration to start the reaction.

[0794] (8) Centrifuge the 384-well plate at 1000 rpm for 60 seconds, shake to mix, and incubate at room temperature for 60 minutes.

[0795] (9) Prepare stop solution (200 μM SAM (Sigma, Cat. No. A7007)) with 1× reaction buffer.

[0796] (10) Add 5 μL of stop solution, centrifuge at 1000 rpm for 60 seconds, transfer all the solutions in each well to FlashPlate, and incubate at room temperature for 60 minutes.

[0797] (11) Readings were made using MicroBeta2.

[0798] (12) Calculation formula

[0799] Inhibition%=100-(RLU-Mean(NC)) / (Mean(PC)-Mean(NC))*100

[0800] RLU: Luminescence value of the sample;

[0801] Mean (NC): average luminescence value of negative control;

[0802] Mean (PC): average luminescence value of positive control;

[0803] Dose-effect curves were fitted using GraphPad Prism 5 software, and IC50 was calculated using the 'log[inhibitor] vs. response-variable slope' procedure.

[0804] Table 3 Test results of the inhibitory effect of compounds on PRMT5

[0805] Experimental conclusion: The compound of the present invention is a PRMT5 inhibitor synergistic with MTA and has a significant inhibitory effect.

[0806] Experimental Example 3: Evaluation of compound efflux ratio using Caco-2 cell model

[0807] 3.1 Instruments, Equipment and Materials

[0808] (1) Caco-2 cells were purchased from the American Type Culture Collection (ATCC).

[0809] (2) The control drug propranolol was purchased from Sigma (St. Louis, MO). Digoxin was purchased from MCE. Minoxidil was purchased from the National Institute for Food and Drug Control.

[0810] (3) FBS medium was purchased from Sigma, DMEM was purchased from Corning (Cambridge, MA), non-essential amino acids (NEAA), Hank's balanced salt solution (HBSS), and trypsin / EDTA were purchased from Thermo Fisher Scientific. Penicillin and streptomycin were purchased from Solebro.

[0811] (4) HTS-96-well Transwell plates and other sterile consumables were purchased from Corning.

[0812] (5) Millicell resistance measurement system was purchased from Millipore. Vision was purchased from Nexcelom Bioscience, Infinite200PRO microplate reader was purchased from Tecan, and MTS2 / 4 orbital shaker was purchased from IKA Labortechnik.

[0813] 3.2 Experimental design

[0814] 3.2.1 Cell culture and plating

[0815] (1) High-glucose (4.5 g / L) DMEM medium containing L-glutamine, supplemented with 10% fetal bovine serum, 0.1 mg / mL streptomycin, and 100 units of penicillin was used for cell culture.

[0816] (2) Caco-2 cells were cultured in cell culture flasks in an incubator set at 37°C, 5% CO2, and a relative humidity of 95%. Cells were seeded into Transwell plates when they reached a confluence of 70-90%.

[0817] (3) Before cell inoculation, add 50 μL of cell culture medium to each well of the upper chamber of the Transwell and 25 mL of cell culture medium to the lower culture plate. Place the culture plate in a 37°C, 5% CO2 incubator for 1 hour before inoculating cells.

[0818] (4) After cell digestion, transfer the cell suspension to a round-bottom centrifuge tube and centrifuge at 120g for 5 minutes.

[0819] (5) Resuspend the cells in culture medium to a final concentration of 6.86×10 5 Cells / mL. 50 μL of cell suspension was added to the chamber of a 96-well Transwell culture plate, with a final seeding density of 2.4×10 5 cells / cm2.

[0820] (6) Start changing the medium 48 hours after inoculation and culture for 14-18 days, changing the medium every other day.

[0821] (7) The medium replacement process is as follows: separate the Transwell chamber from the receiving plate, discard the medium in the receiving plate first and then discard the medium in the Transwell chamber, and finally add 75 μL of fresh medium to each chamber and 25 mL of fresh medium to the receiving plate.

[0822] 3.2.2 Evaluation of cell monolayer integrity

[0823] (1) After 14-18 days of culture, Caco-2 cells are fully confluent and differentiated. At this point, they can be used for penetration assays.

[0824] (2) The resistance of the monolayer membrane was measured using a resistance meter (Millipore, USA) and the resistance of each pore was recorded.

[0825] (3) After the measurement, place the Transwell culture plate back into the incubator.

[0826] (4) Calculation of resistance: resistance (ohms) × membrane area (cm2) = TEER (ohm·cm2). If TEER < 230 ohms·cm 2 , then the hole cannot be used for penetration test.

[0827] 3.2.3 Solution preparation

[0828] (1) Prepare 1 L of buffer (HBSS, 10 mM HEPES, pH 7.4). Weigh 2.38 g HEPES and 0.35 g sodium bicarbonate, dissolve them in 900 mL of pure water, then add 100 mL of 10× HBSS, stir well, adjust the pH to 7.4, and filter.

[0829] (2) Prepare a DMSO stock solution of the test substance. Prepare a 1 mM DMSO stock solution of the control drug. Dilute with buffer to obtain a 5 μM working solution. Dilute the test substance with buffer to obtain a 5 μM working solution. The final DMSO content of the system is 0.5%.

[0830] (3) Preparation of dosing solution:

[0831] (4) Prepare the receiving end solution:

[0832] 3.2.4 Drug penetration test

[0833] (1) Remove the Caco-2 Transwell plate from the incubator. Rinse the cell monolayer twice with buffer and incubate at 37°C for 30 minutes.

[0834] (2) To measure the transport rate of compounds from the apical to the basolateral side, 125 μL of test compound and control solution was added to each well (apical side) of the insert, and 235 μL of HBSS (10 mM HEPES, pH 7.4) buffer was added to each well of the test compound and control solution receiving plate (basolateral side). 50 μL of the sample was transferred from the apical solution and added to 200 μL of acetonitrile containing internal standards (100 nM alprazolam, 200 nM labetalol, 200 nM caffeine, and 2 μM ketoprofen) as the 0-minute apical administration sample for detection.

[0835] (3) To measure the transport rate of the compound from the basolateral to the apical side, 285 μL of the test compound and control drug solutions were added to each well of the receiving plate (basolateral side), 75 μL of HBSS (10 mM HEPES, pH 7.4) buffer was added to each well of the test compound solution insert (apical side), and 75 μL of HBSS (10 mM HEPES, pH 7.4) buffer was added to each well of the control drug solution insert (apical side). 50 μL of the sample was transferred from the basolateral solution and added to 200 μL of acetonitrile containing internal standards (100 nM alprazolam, 200 nM labetalol, 200 nM caffeine, and 2 μM ketoprofen) as the 0-minute basolateral administration sample for detection.

[0836] (4) Incubate in a 37°C CO2 incubator for 2 hours.

[0837] (5) After the transport experiment, transfer 50 μL of sample from the dosing end (the top end in the Ap→Bl direction and the base end in the Bl→Ap direction) to 200 μL of acetonitrile containing internal standards (100 nM alprazolam, 200 nM labetalol, 200 nM caffeine and 2 μM ketoprofen). Transfer 50 μL of sample from the receiving end (the base end in the Ap→Bl direction and the top end in the Bl→Ap direction) to 200 μL of acetonitrile containing internal standards (100 nM alprazolam, 200 nM labetalol, 200 nM caffeine and 2 μM ketoprofen). Vortex at 1000 rpm for 10 minutes. Quench the sample at each time point and centrifuge at 3220 g for 30 minutes. Transfer 100 μL of the supernatant of each sample to a 96-well plate, and add 100 μL of pure water to the corresponding well. The sample analysis plate was vortexed at 1000 rpm for 2 minutes before LC / MS / MS analysis. All incubation samples were performed in duplicate.

[0838] (6) After the two-hour transport experiment, the fluorescence value was measured. A 10 mM lucifer yellow stock solution was prepared with water and diluted to 100 μM with transport buffer. 100 μL of lucifer yellow solution was added to the top of the Transwell chamber and 300 μL of transport buffer was added to the base. The cells were incubated at 37°C in a CO2 incubator for 30 minutes. 80 μL of solution was directly removed from the top and base (using the basolateral wells) and transferred to a new 96-well plate. The cell fluorescence value (to detect membrane integrity) was measured using a microplate reader with an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

[0839] 3.3 Data Analysis

[0840] Data calculations were performed using Excel. Peak areas were calculated from ion chromatography results. The apparent permeability coefficient (P app , unit: cm / s×10 -6 ) is calculated using the following formula:

[0841] In the formula: V A is the volume of the receiving end solution (Ap→Bl is 0.235 mL, Bl→Ap is 0.075 mL), Area is the Transwell-96 well plate membrane area (0.143 cm 2 ); time is the incubation time (unit: s), [drug] acceptor is the drug concentration at the receiving end (relative value, calculated using the corresponding Area Ratio), [drug]initial,donor is the initial drug concentration at the dosing end (relative value, calculated using the corresponding Area Ratio).

[0842] The efflux rate is calculated using the following formula:

[0843] In the formula: P app(B-A) is the apparent permeability coefficient from the base to the top; P app(A-B) is the apparent permeability from the top to the base.

[0844] Table 4 Excretion ratio of compounds

[0845] Experimental conclusion: Compared with existing compounds, the efflux effect of the compounds of the present invention is significantly reduced.

[0846] MRTX1719 has the following structure:

[0847] Experimental Example 4: Study on the metabolic stability of compounds in hepatocytes

[0848] 4.1 Materials

[0849] Hepatocytes were stored in liquid nitrogen. Detailed information is shown in the table below.

[0850] 4.2 Experimental design

[0851] 4.2.1 Preparation of compound working solution

[0852] The test substance and control drug verapamil powder were prepared into a high concentration stock solution of 10 mM using DSMO, and diluted to a 100 μM working solution using 50% acetonitrile / water before use. The final concentration of the test substance and verapamil was 1 μM.

[0853] 4.2.2 Preparation of Hepatocytes

[0854] (1) Hepatocyte resuscitation medium includes Williams' Medium E, Isotonic Percoll, DPBS, GlutaMAX, HEPES, FBS, human recombinant insulin, and dexamethasone. Mix 49.5 mL of Williams' Medium E and 0.5 mL of GlutaMAX as the incubation medium.

[0855] (2) Preheat the hepatocyte thawing solution and incubation solution in a 37°C water bath for at least 15 minutes before use. Take a tube of cryopreserved hepatocytes and ensure that the hepatocytes are still frozen before thawing. Quickly place the hepatocytes in a 37°C water bath and gently shake until all ice crystals are dispersed. Spray with 75% ethanol and transfer to a biosafety cabinet.

[0856] (3) Pour the contents of the hepatocyte tubules into a centrifuge tube containing 50 mL of recovery medium and centrifuge at 100 g for 10 minutes. After centrifugation, aspirate the recovery medium and add enough incubation medium to obtain a cell density of approximately 1.0 × 10 6 cells / mL of cell suspension.

[0857] (4) Count the hepatocytes and determine the viable cell density using Cellometer Vision. The viability of the hepatocytes must be greater than 75%. Dilute the hepatocyte suspension with incubation medium to a viable cell density of 0.5×10 6 cells / mL.

[0858] (5) A portion with a density of 0.5×10 6 A hepatocyte suspension containing 10 cells / mL was inactivated by boiling in water for 5 minutes as a negative control. This inactivation facilitates the investigation of substrate conversion mediated by non-cellular enzymes.

[0859] 4.2.3 Test methods

[0860] (1) Transfer 198 μL of live or inactivated cell suspension to a 96-well deep-well plate. Place the plate on a vortex and preheat in an incubator for 10 minutes. Incubate live cells in duplicate and inactivated cells in a single parallel.

[0861] (2) Add 2 μL of 100 μM test substance or verapamil to each well to initiate the reaction, and place the deep-well plate back on the incubator vortexer.

[0862] (3) Incubate the sample. At 0, 15, 30, 60, 90, and 120 minutes, take 25 μL of the suspension and terminate the reaction by adding 150 μL of acetonitrile containing internal standards (200 nM alprazolam, 200 nM labetalol, 2 μM ketoprofen, and 200 nM caffeine). Vortex for 10 minutes and centrifuge at 3220 g and 4°C for 30 minutes. After centrifugation, take 100 μL of the supernatant and mix it with 100 μL of ultrapure water for UPLC-MS / MS analysis.

[0863] 4.3 Data Analysis

[0864] All data calculations were performed using Microsoft Excel. Peak areas were determined by extracting ion spectra. The in vitro half-life (t 1 / 2 ).

[0865] In vitro half-life (t 1 / 2 ) calculated by slope: in vitro t 1 / 2 =0.693 / k

[0866] Table 5 Metabolic stability of compounds in hepatocytes

[0867] Experimental conclusion: The compounds of the present invention are metabolically stable in mouse hepatocytes in vitro.

[0868] Experimental Example 5: Cell Anti-Proliferation Experimental Method

[0869] 5.1 Materials and Cells

[0870] HCT116MTAP Deletion cells were from Pharmaron (China); HCT116 cells were from ATCC (USA); McCoy's 5A medium was purchased from Invitrogen (USA); penicillin-streptomycin and fetal bovine serum were purchased from Gibco (USA); 384-well plates were purchased from PerkinElmer (USA); and Cell-Titer Glo reagent was purchased from Promega (USA).

[0871] 5.2 Compound Storage

[0872] Compound Dissolution: All compounds were dissolved in dimethyl sulfoxide (DMSO) and stored in a dry place at room temperature for short-term storage for 3 months or at -20°C for long-term storage.

[0873] 5.3 Cell culture and passaging

[0874] Cells were cultured in strict accordance with ATCC guidelines. Cell culture medium (McCoy's 5A medium + 10% fetal bovine serum + 1% penicillin + streptomycin) was transferred to a 15 mL centrifuge tube and centrifuged at 1000 rpm for 5 minutes. The supernatant was removed, and the cells were resuspended in complete culture medium. The cells were seeded into culture dishes at the desired density and cultured in an incubator at 37°C in a humidified atmosphere of 95% air and 5% carbon dioxide. Depending on cell growth, the culture medium was replenished or the cells were passaged every 2-3 days.

[0875] 5.4 Cell proliferation activity detection

[0876] When cells reached approximately 90% confluency in the culture dish, they were washed twice with PBS and trypsinized to single cells. Cells were counted and plated in 384-well plates (50 cells / well) at 40 μl per well. The plates were equilibrated at 37°C and 5% CO2 for 10-15 minutes. Compounds were injected into the 384-well plates using an Echo550. A three-fold dilution gradient of 10 was set up for each compound, with duplicate wells containing 0.1% DMSO. The 384-well plates were incubated in a cell culture incubator for 10 days.

[0877] Then, 40 μl of cell proliferation detection reagent (CTG) was added to the 384-well plate and shaken to mix. The 384-well plate was then incubated in the dark at 37°C and 5% carbon dioxide for 30 minutes. The reading was performed using the Envision multifunctional microplate reader. The formula for calculating the percentage of compound inhibition is as follows: Percentage inhibition = 100-(Signal value 药物处理组 -Signal value day0_cell ) / (Signal value 阴性对照组 -Signal value day0_cell ) × 100. GraphPad 8.0 software was used to analyze the GI tract according to different drug concentrations and their corresponding inhibition rates. 50 Draw curves, analyze data, and get the final GI 50 The results are shown in Table 6, where GI 50 ≤0.1μM is A, 0.1μM<GI 50 ≤1μM is B, 1μM<GI 50 C is ≤10μM.

[0878] Table 6 Test results of the anti-proliferative activity of the compounds of the present invention

[0879] In addition, the compounds of the present invention also have selectivity for mutant HCT116 cells, for example, compounds 71 ​​and 72 have a selective effect on HCT116 cells. MTAP Deletion GI 50 ≤0.1μM, but the GI of HCT116 50 The selectivity is more than 10 times.

[0880] Experimental Example 6: Cell SDMA In-cell Western blotting

[0881] 6.1 Materials and Cells

[0882] HCT116 MTAP Deletion Cells were from Horizon; HCT116 cells were from ATCC; RPMI-1640 medium was purchased from ATCC (USA); penicillin-streptomycin was purchased from Gibco (USA); fetal bovine serum was purchased from ExCell; 96-well plates were purchased from Corning (USA); Symmetric Di-Methyl Arginine Motif [sdme-RG] antibody was purchased from CST (USA); IRDye 800CW Goat anti-Rabbit IgG secondary antibody was purchased from LI-COR (USA), and CellTag 700 stain was purchased from LI-COR (USA).

[0883] 6.2 Compound Storage

[0884] Compound Dissolution: All compounds were dissolved in dimethyl sulfoxide (DMSO) and stored at -20°C for long-term storage.

[0885] 6.3 Cell culture and passaging

[0886] Cells were cultured in strict accordance with ATCC guidelines. Cell culture medium (RPMI-1640 medium + 10% serum + 1% penicillin + streptomycin) was transferred to a 15 mL centrifuge tube and centrifuged at 1000 rpm for 5 minutes. The supernatant was removed and the cells were resuspended in complete culture medium. The cells were seeded into culture dishes at the desired density and cultured in an incubator at 37°C in a humidified atmosphere of 95% air and 5% carbon dioxide. The culture medium was replenished or passaged every 2-3 days, depending on cell growth.

[0887] 6.4 SDMA in-cell western blot

[0888] When the cells reached approximately 90% confluence in the culture dish, they were washed twice with PBS, trypsinized, and 100 μL per well was seeded into a 96-well plate (800 cells / well). The cells were cultured overnight at 37°C in a 5% CO2 incubator. 50 μL of the compound at 3x the final concentration was added to the cell culture plate. Each compound was diluted 10 times in a 3-fold series in duplicate wells. The final DMSO concentration was 0.5%. The cells were cultured in a 37°C, 5% CO2 incubator for 96 hours.

[0889] Add 150 μL of 8% paraformaldehyde to each well and incubate at room temperature for 15 minutes. Discard the supernatant, wash the plate with PBS, and add 200 μL of freshly prepared 1x Permeabilization buffer to each well and incubate at room temperature for 30 minutes. Discard the supernatant, add 200 μL of 1x Blocking buffer to each well and incubate at room temperature for 2 hours. Discard the supernatant, add 50 μL of primary antibody (CST, diluted 1:500 in 1x Incubation buffer) to each well and incubate at 4°C overnight. Discard the supernatant, add 250 μL of 1x Washing buffer to each well and wash three times. Add 50 μL of secondary antibody (IRDye 800CW Goat anti-Rabbit IgG and CellTag 700 dye, diluted 1:800 and 1:500 in Incubation buffer) to each well and incubate at room temperature for 1 hour. Discard the supernatant and wash the plate with 1x Washing buffer. Signal detection was performed using a Licor Odyssey CLX. The formula for calculating the percentage of compound inhibition rate is as follows: Inhibition rate percentage = 100-(signal value 药物处理组 -Signal value 背景值 ) / (signal value 0.5% DMSO treatment group - signal value 背景值 ) × 100. According to different drug concentrations and their corresponding inhibition rates, IC was calculated using GraphPad 8.0 software. 50 Draw curves, analyze data, and obtain the final IC 50 The results are shown in Table 7, where IC 50 ≤0.1μM is A, 0.1μM<IC 50 ≤1μM is B, 1μM<IC 50 C is ≤10μM.

[0890] Table 7 Cellular SDMA inhibitory activity

[0891] Experimental Example 7 In vivo pharmacodynamic study in LU99 CDX model

[0892] 7.1 Experimental Materials: LU99 cells were obtained from JCRB (Japan); RPMI-1640 and 0.25% trypsin-EDTA were purchased from Gibco (USA); fetal bovine serum was purchased from Dongling (China); PBS was purchased from Hyclone (USA); penicillin-streptomycin was purchased from Meilun Biotechnology (China); and Matrigel was purchased from Corning (USA).

[0893] 7.2 Animal Information: Female BALB / c nude mice, 6-8 weeks old, weighing 18-22 g, were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd. The mice were housed in an SPF-grade environment with individual ventilation in each cage. All animals had free access to a standard certified commercial laboratory diet and free drinking water.

[0894] 7.3 Experimental methods:

[0895] 7.3.1 Cell Culture: Human large cell lung cancer LU99 cells were cultured as monolayers in RPMI-1640 medium supplemented with 10% fetal bovine serum in a 37°C, 5% CO2 incubator. Cells were routinely digested and passaged twice weekly using trypsin-EDTA. When the desired cell number was reached, cells were harvested and counted.

[0896] 7.3.2 Cell inoculation: 0.2 mL (5 × 10 6 LU99 cells (with Matrigel, volume ratio of 1:1) were subcutaneously inoculated on the right back of each mouse, and the average tumor volume reached approximately 150 mm 3 At 4 hr, the patients were randomly divided into groups according to the tumor volume and animal body weight and began to receive the drugs.

[0897] 7.3.3 Administration: Compound 72 was administered at a dose of 30 mpk, PO, once daily (QD) for 3 weeks, with 6 mice per group.

[0898] 7.3.4 Tumor Measurement and Experimental Indicators:

[0899] Tumor diameter was measured twice a week using a vernier caliper. Tumor volume was calculated using the formula: V = 0.5a × b 2 , a and b represent the long diameter and short diameter of the tumor, respectively. The body weight of mice was measured twice a week.

[0900] The antitumor efficacy of the compound was evaluated by tumor growth inhibition rate (TGI).

[0901] TGI (%) = [(1-(average tumor volume of a treatment group at the end of drug administration - average tumor volume of the treatment group at the beginning of drug administration)) / (average tumor volume of the solvent control group at the end of treatment - average tumor volume of the solvent control group at the beginning of treatment)] × 100%.

[0902] The experimental results are shown in Figures 1 and 2. No mice became ill or died during the experiment.

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof: in: Z1, Z2 and Z3 are independently selected from N, CD or CH, and at least one of them is N; Ring A is phenyl or a 5-6 membered heteroaryl group; R1 is selected from H, D, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents; R2 is selected from H, D, -C 0-6 Alkylene-halogen, -C 0-6 Alkylene -CN, -C 0-6 Alkylene-OR a 、-C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; m = 0, 1, 2, or 3; Wherein R is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R on the same carbon atom form C=O, C=S, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; or two R on adjacent atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents; R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, preferably H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, which is optionally substituted by one or more D, halogen, C 1-6 Alkyl or C 1-6 haloalkyl substitution; R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group; Among them, ring A, R1, R2, R, R', R a 、R b and R c Each group in may be optionally substituted by D up to full deuteration.

2. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof: in: Z1, Z2 and Z3 are independently selected from N, CD or CH, and at least one of them is N; Ring A is phenyl or a 5-6 membered heteroaryl group; R1 is selected from H, D, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents; R2 is selected from H, D, -C 0-6 Alkylene-halogen, -C 0-6 Alkylene -CN, -C 0-6 Alkylene-OR a 、-C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; m = 0, 1, 2, or 3; Wherein R is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R on the same carbon atom form C=O, C=S, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; or two R on adjacent atoms form a C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents; R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, preferably H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group; Among them, ring A, R1, R2, R, R', R a 、R b and R c Each group in may be optionally substituted by D up to full deuteration.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein ring A is a 5-6 membered heteroaryl group; Preferably selected from the following: More preferably, they are selected from the following: More preferably wherein R1 and R2 are as defined in claim 2.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R2 is selected from H, halogen, CN, -C 0-6 Alkylene-OR a 、-C 0-6 Alkylene-NR b R c 、C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-8 Cycloalkyl; preferably selected from H, -C 0-6 Alkylene-OR a 、C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl; more preferably selected from H, F, Cl, Br, CH2CH2OH, Me, Et, Pr, iPr, CF3 or cyclopropyl; more preferably C 1-6 Alkyl or C 1-6 Haloalkyl, especially Me.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R1 is selected from C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; preferably selected from 4-7 membered heterocyclic group, C 6-10 Aryl or 5-6 membered heteroaryl; more preferably selected from phenyl, pyrrolidinyl, pyrazolidinyl, piperidinyl or pyridonyl.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R is selected from halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R on the same carbon atom form C=O, C=S or C=O with the carbon atom; 3-6 Cycloalkyl; or two R on adjacent atoms form a C 3-6 Cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, for example cyclopentenyl, phenyl, thienyl or pyridyl.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; preferably, R' is selected from H, D, halogen, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; preferably, R' is selected from H, D, halogen, CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 6-10 Aryl or 5-10 membered heteroaryl; preferably, R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-6 Cycloalkyl or 5-6 membered heterocyclic group.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, having the following general formula: in, represents a single bond or a double bond; X is selected from NR N , CR 2b R 2b ’, CR 2b R 2b ’-CR 2b R 2b ’ or CR 2b =CR 2b ’; Y1 is selected from N or CR Y1 ; Y2 is selected from N or CR Y2 ; Y3 is selected from N or CR Y3 ; Y4 is selected from N or CR Y4 ; where R N Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide; R 1a 、R 2a 、R 3a 、R 4a 、R 5a 、R 1b 、R 1b '、R 2b 、R 2b '、R 3b and R 4b has the same meaning as R in claim 1 or 2; R Y1 、R Y2 、R Y3 and R Y4 has the same definition as R' above; Other groups are as defined in any one of claims 1 to 7.

9. The compound of claim 8, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, having the following general formula: in, R2 is selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; R 1a Selected from H, D, halogen, CN, OR a or NR b R c ; R 2a is selected from H, D, halogen or CN; R 3a Selected from H or D; R 4a Selected from OR a or NR b R c ; R 5a Selected from H, D or CN; Or, R 3a 、R 4a and the carbon atom to which they are attached form a 4-6 membered heterocyclyl or a 5-6 membered heteroaryl, which is optionally substituted with 1, 2, 3 or 4 R' substituents; Wherein R' is selected from H, D, C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

10. The compound of claim 9, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R2 is selected from H, C 1-6 Alkyl or C 1-6 alkyl halide; R 1a is halogen, preferably F; R 2a is selected from H, D or halogen; R 3a H or D; R 4a is OR a ; R 5a For CN; Or, R 3a 、R 4a and the carbon atom to which they are attached form a furanyl or dihydrofuranyl group, which is optionally substituted with 1, 2, 3, or 4 R' substituents; Wherein R' is selected from H, D, C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-6 Cycloalkyl or 5-6 membered heterocyclic group; R a Selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl or 4-7 membered heterocyclic group.

11. The compound of claim 9, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R2 is selected from H, C 1-4 Alkyl or C 1-4 alkyl halide; R 1a is halogen, preferably F; R 2a is selected from H, D or halogen; R 3a H or D; R 4a is OR a ; R 5a For CN; Or, R 3a 、R 4a and the carbon atom to which they are attached form a dihydrofuranyl group substituted with 1, 2, 3, or 4 R' substituents; Wherein R' is selected from H, D, C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-6 Cycloalkyl or 5-6 membered heterocyclic group, preferably cyclopropyl; R a Selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl or 5-6 membered heterocyclic group.

12. The compound of claim 9, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R2 is Me; R 1a is F; R 2a is H or Cl; R 3a 、R 4a and the carbon atom to which they are attached form a dihydrofuranyl group substituted with 1, 2, 3, or 4 R' substituents; R 5a For CN; wherein R' is selected from H or Me, or two R' on the same or different atoms form a cyclopropyl group with the atom.

13. The compound of claim 8, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, having the following general formula: in, represents a single bond or a double bond; X is selected from NR N , CR 2b R 2b ’, CR 2b R 2b ’-CR 2b R 2b ’ or CR 2b =CR 2b ’; R2 is selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; R 1b and R 1b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; R 3b and R 4b Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 haloalkyl; or R 3b 、R 4b and the carbon atoms to which they are attached form C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents; where R N Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide; R 2b and R 2b 'Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 haloalkyl; or R on the same or different atoms 2b and R 2b ' and the carbon atoms to which they are connected form C 3-6 Cycloalkyl or 4-7 membered heterocyclic group; or R 2b ' and R 3b and the carbon atoms to which they are attached form C 6-10 Aryl or 5-10 membered heteroaryl; R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

14. The compound of claim 13, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein represents a single bond or a double bond; X is selected from NR N , CR 2b R 2b ' or CR 2b =CR 2b '; R2 is selected from H, C 1-6 Alkyl or C 1-6 alkyl halide; R 1b and R 1b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; R 3b and R 4b Independently selected from H, D, OR a NR b R c 、C 1-6 Alkyl or C 1-6 haloalkyl; or R 3b 、R 4b and the carbon atoms to which they are attached form C 3-6 cycloalkyl, 4-7 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents; where R N Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide; R 2b and R 2b 'Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 haloalkyl; or R on the same or different atoms 2b and R 2b ' and the carbon atoms to which they are connected form C 3-6 Cycloalkyl; or R 2b ' and R 3b and the carbon atoms to which they are attached form a phenyl group or a 5-6 membered heteroaryl group; R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide; R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

15. The compound of claim 8, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, having the following general formula: in, X is selected from NR N or CR 2b R 2b '; R2 is selected from H, C 1-6 Alkyl or C 1-6 alkyl halide; R 1b and R 1b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; Y1 is selected from N or CR Y1 ; Y2 is selected from N or CR Y2 ; Y3 is selected from N or CR Y3 ; Y4 is selected from N or CR Y4 ; where R N Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide; R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 haloalkyl; or R 2b and R 2b ' and the carbon atoms to which they are connected form C 3-6 Cycloalkyl; R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide; R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

16. The compound of claim 15, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is selected from NR N or CR 2b R 2b '; R2 is selected from H, C 1-4 Alkyl or C 1-4 alkyl halide; R 1b and R 1b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O; Y1 is selected from N or CR Y1 ; Y2 is selected from N or CR Y2 ; Y3 is selected from N or CR Y3 ; Y4 is selected from N or CR Y4 ; where R N Selected from H, C 1-4 Alkyl or C 1-4 alkyl halide; R 2b and R 2b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 2b and R 2b ' and the carbon atoms to which they are connected form C 3-6 Cycloalkyl; R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide; R a 、R b and R c Independently selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl, or R b and R c and the nitrogen atom to which they are attached form a 5-6 membered heterocyclic group.

17. The compound of claim 15, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is selected from NR N or CR 2b R 2b '; R2 is Me; R 1b and R 1b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O; Y1 is selected from N or CR Y1 ; Y2 is selected from N or CR Y2 ; Y3 is selected from N or CR Y3 ; Y4 is selected from N or CR Y4 ; where R N selected from H or Me; R 2b and R 2b 'Independently selected from H or Me, or R 2b and R 2b 'and the carbon atoms to which they are attached form a cyclopropyl group; R Y1 、R Y2 、R Y3 and R Y4 Selected from H, F, CN, Me, CF3 or OMe.

18. The compound of claim 8, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, having the following general formula: in, represents a single bond or a double bond; R2 is selected from H, C 1-6 Alkyl or C 1-6 alkyl halide; R 1b and R 1b 'Independently selected from H, C 1-6 Alkyl or C 1-6 haloalkyl; or R 1b 、R 1b ' and the carbon atoms they connect to form C=O or C=S; R 2b and R 2b 'Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide; R 3b is selected from H, D, halogen or CN; R 4b Selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide; or R 2b ' and R 3b and the carbon atoms to which they are attached form a phenyl group or a 5-6 membered heteroaryl group; or R 3b 、R 4b and the carbon atoms to which they are attached form C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents; R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 or two R' on the same or different atoms form a C 3-8 Cycloalkyl or 4-7 membered heterocyclic group; R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

19. The compound of claim 18, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein represents a single bond or a double bond; R2 is selected from H, C 1-4 Alkyl or C 1-4 alkyl halide; R 1b and R 1b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O; R 2b and R 2b 'Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-4 Alkyl or C 1-4 alkyl halide; R 3b Selected from H or D; R 4b Selected from H, D, OR a NR b R c 、C 1-4 Alkyl or C 1-4 alkyl halide; or R 2b ' and R 3b and the carbon atom to which they are attached forms a phenyl group; or R 3b 、R 4b and the carbon atoms to which they are attached form C 3-6 cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents; R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl or C 1-6 alkyl halide; R a 、R b and R c Independently selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.

20. The compound of claim 18, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein represents a single bond or a double bond; R2 is Me; R 1b and R 1b 'Independently selected from H, D, C 1-4 Alkyl or C 1-4 haloalkyl; or R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O; R 2b Selected from H, D, F, Cl, Br, I, Me or CF3; R 2b ' is selected from H, D, F, Cl, Br, I, Me, CF3 or OMe; R 3b H or D; R 4b is selected from H, D, Me, OMe or O-cyclopropyl; Or, R 3b 、R 4b and the carbon atom to which they are attached forms a phenyl, cyclopentenyl, or thienyl group; Or, R 2b '、R 3b and the carbon atom to which they are attached form a phenyl group.

21. The compound of claim 8, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, having the following general formula: in: R1 and R2 are as defined in any one of claims 1 and 3-6; Preferably, R1 is a 4-7 membered heterocyclyl group, which is optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; Wherein R is selected from H, D, halogen, CN, C 1-6 Alkyl or C 1-6 haloalkyl; or two R on the same carbon atom form C=O or C=S with the carbon atom; or two R on adjacent atoms form phenyl or 5-6 membered heteroaryl with the atom, which is optionally substituted with 1, 2, 3 or 4 R' substituents; R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl.

22. The compound of claim 21, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R1 is a 5-6 membered heterocyclyl group, which is optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; Wherein R is selected from H, D, halogen, CN, C 1-6 Alkyl or C 1-6 haloalkyl; or two R on the same carbon atom form C=O or C=S with that carbon atom; or two R on adjacent atoms form phenyl with said atom, which is optionally substituted with 1, 2, 3 or 4 R' substituents; R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl; where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

23. The compound of claim 21, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R1 is selected from pyrrolidinyl or piperidinyl, optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 R substituents; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; Wherein R is selected from H, D, halogen, CN, C 1-6 Alkyl or C 1-6 haloalkyl; or two R on the same carbon atom form C=O with the carbon atom; or two R on adjacent atoms form phenyl with the atom, which is optionally substituted with 1, 2, 3 or 4 R' substituents; R' is selected from H, D, halogen, CN, C 1-6 Alkyl, C 1-6 halogenated alkyl, phenyl or 5-6 membered heteroaryl.

24. The compound of claim 8, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, having the following general formula: in: represents a single bond or a double bond; X is selected from CR 2b R 2b ’, CR 2b R 2b ’-CR 2b R 2b ’ or CR 2b =CR 2b ’; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; R 3b 、R 4b and the carbon atoms to which they are attached form C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with 1, 2, 3 or 4 R' substituents; R 2b and R 2b 'Independently selected from H, D, halogen, CN, C 1-6 Alkyl or C 1-6 alkyl halide; R' is selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl.

25. The compound of claim 24, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein represents a double bond; X is selected from CR 2b R 2b ’, CR 2b R 2b ’-CR 2b R 2b ’ or CR 2b =CR 2b ’; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; R 3b 、R 4b and the carbon atom to which they are attached form a phenyl group, which is optionally substituted with 1, 2, 3, or 4 R' substituents; R 2b and R 2b 'Independently selected from H, D, halogen, CN, C 1-6 Alkyl or C 1-6 alkyl halide; R' is selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl; where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl.

26. The compound of claim 24, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein represents a double bond; X is selected from CR 2b R 2b ' or CR 2b R 2b '-CR 2b R 2b '; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O; R 3b 、R 4b and the carbon atom to which they are attached form a phenyl group, which is optionally substituted with 1, 2, 3, or 4 R' substituents; R 2b and R 2b 'Independently selected from H or D; R' is selected from H, D, halogen, CN, C 1-6 Alkyl, C 1-6 halogenated alkyl, phenyl or 5-6 membered heteroaryl.

27. The compound of claim 8, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, having the following general formula: in: X is CR 2b R 2b '; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; Y1 is selected from N or CR Y1 ; Y2 is selected from N or CR Y2 ; Y3 is selected from N or CR Y3 ; Y4 is selected from N or CR Y4 ; R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, CN, OR a NR b R c 、C(O)OR a 、C(O)NR b R c 、S(O)R a 、S(O)2R a 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl.

28. The compound of claim 27, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is CR 2b R 2b '; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; Y1 is selected from N or CR Y1 ; Y2 is selected from N or CR Y2 ; Y3 is selected from N or CR Y3 ; Y4 is selected from N or CR Y4 ; R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R Y1 、R Y2 、R Y3 and R Y4 R' is independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl; where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

29. The compound of claim 27, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is CR 2b R 2b '; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O; Y1 is CR Y1 ; Y2 is CR Y2 ; Y3 is CR Y3 ; Y4 is CR Y4 ; R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, CN, C 1-6 Alkyl, C 1-6 halogenated alkyl, phenyl or 5-6 membered heteroaryl.

30. The compound of claim 8, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, having the following general formula: in: X is CR 2b R 2b '; R2 is selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl or 4-7 membered heterocyclic group; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; Y1 is CR Y1 ; Y2 is CR Y2 ; Y3 is CR Y3 ; Y4 is CR Y4 ; R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, CN, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2- 6 alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; or R Y1 and R Y2 、R Y2 and R Y3 、R Y3 and R Y4 , and the atoms they connect together form C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, which is optionally substituted by one or more D, halogen, C 1-6 Alkyl or C 1-6 haloalkyl substitution; where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

31. The compound of claim 30, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is CR 2b R 2b '; R2 is Me, Et or cyclopropyl; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O; Y1 is CR Y1 ; Y2 is CR Y2 ; Y3 is CR Y3 ; Y4 is CR Y4 ; R 2b and R 2b 'Independently selected from H or D; R Y1 Selected from H, D, Cl, F, CN, Me, CF3 or OMe; R Y2 is selected from H, D, Me, Et, iPr, CF3, cyclopropyl, OMe, OEt, OiPr, OCF3, O-cyclopropyl, prop-1-en-2-yl or phenyl; R Y3 is selected from H, D, Cl, F, Me, Et, iPr, CF3, cyclopropyl, prop-1-en-2-yl, OMe or O-cyclopropyl; R Y4 Selected from H, D or Me; or R Y1 and R Y2 、R Y2 and R Y3 、R Y3 and R Y4 , and the atoms they connect together form C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, which is optionally substituted by one or more D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl substitution.

32. The compound of claim 30, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is CR 2b R 2b '; R2 is selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl or 4-7 membered heterocyclic group; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; Y1 is CR Y1 ; Y2 is CR Y2 ; Y3 is CR Y3 ; Y4 is CR Y4 ; R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R Y1 、R Y2 、R Y3 and R Y4 Independently selected from H, D, halogen, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; where R Y1 and R Y3 At least one of them is not H or D; where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

33. The compound of claim 32, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is CR 2b R 2b '; R2 is selected from C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; Y1 is CR Y1 ; Y2 is CR Y2 ; Y3 is CR Y3 ; Y4 is CR Y4 ; R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R Y1 and R Y3 Independently selected from H, D, halogen, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl or 4-7 membered heterocyclic group; R Y2 and R Y4 Independently selected from H, D, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl; where R Y1 and R Y3 At least one of them is not H or D; where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

34. The compound of claim 32, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is CR 2b R 2b '; R2 is Me, Et or cyclopropyl; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O; Y1 is CR Y1 ; Y2 is CR Y2 ; Y3 is CR Y3 ; Y4 is CR Y4 ; R 2b and R 2b 'Independently selected from H or D; R Y1 Selected from H, D, Cl, F, Me, CF3 or OMe; R Y2 is selected from H, D, Et, iPr, OiPr, O-cyclopropyl or prop-1-en-2-yl; R Y3 is selected from H, D, Cl, F, Me, Et, iPr, CF3, cyclopropyl, prop-1-en-2-yl, OMe or O-cyclopropyl; R Y4 Selected from H or D; where R Y1 and R Y3 At least one of them is not H or D.

35. The compound of claim 32, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is CR 2b R 2b '; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O or C=S; Y1 is CR Y1 ; Y2 is CR Y2 ; Y3 is CR Y3 ; Y4 is CR Y4 ; R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R Y1 and R Y3 Independently selected from H, D, halogen, OR a NR b R c 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl or 4-7 membered heterocyclic group; R Y2 and R Y4 Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; where R Y1 and R Y3 At least one of them is not H or D; where R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 4-7 membered heterocyclic group.

36. The compound of claim 35, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is CR 2b R 2b '; R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O; Y1 is CR Y1 ; Y2 is CR Y2 ; Y3 is CR Y3 ; Y4 is CR Y4 ; R 2b and R 2b 'Independently selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R Y1 Selected from H, D, halogen, C 1-6 Alkyl or C 1-6 alkyl halide; R Y2 Selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R Y3 Selected from H, D, halogen, OR a 、C 1-6 Alkyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl; R Y4 Selected from H or D; where R Y1 and R Y3 At least one of them is not H or D; where R a Selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.

37. The compound of claim 35, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein X is CR 2b R 2b '; R2 is Me; R 1b 、R 1b 'and the carbon atoms to which they are attached form C=O; Y1 is CR Y1 ; Y2 is CR Y2 ; Y3 is CR Y3 ; Y4 is CR Y4 ; R 2b and R 2b 'Independently selected from H or D; R Y1 Selected from H, D, Cl, F, Me or CF3; R Y2 selected from H, D or Et; R Y3 is selected from H, D, Cl, F, Me, Et, OMe or cyclopropyl; R Y4 Selected from H or D; where R Y1 and R Y3 At least one of them is not H or D.

38. The compound of claim 8, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, having the general formula: in, R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; R 1a Selected from H, D, halogen, CN, OR a or NR b R c ; R 2a is selected from H, D, halogen or CN; R 3a Selected from H or D; R 4a Selected from OR a or NR b R c ; R 5a Selected from H, D or CN; Or, R 3a 、R 4a and the carbon atom to which they are attached form a 4-6 membered heterocyclyl or a 5-6 membered heteroaryl, which is optionally substituted with 1, 2, 3 or 4 R' substituents; Wherein R' is selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R a 、R b and R c Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, or R b and R c and the nitrogen atom to which they are attached form a 4-7 membered heterocyclic group.

39. The compound of claim 38, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R2 is selected from C 1-6 Alkyl or C 1-6 alkyl halide; R 1a is halogen, preferably F; R 2a is selected from H, D or halogen; R 3a H or D; R 4a is OR a ; R 5a For CN; Or, R 3a 、R 4a and the carbon atom to which they are attached form a furanyl or dihydrofuranyl group, which is optionally substituted with 1, 2, 3, or 4 R' substituents; Wherein R' is selected from H, D, C 1-6 Alkyl or C 1-6 alkyl halide; R a Selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl or 4-7 membered heterocyclic group.

40. The compound of claim 38, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein R2 is selected from C 1-4 Alkyl or C 1-4 alkyl halide; R 1a is halogen, preferably F; R 2a is selected from H, D or halogen; R 3a H or D; R 4a is OR a ; R 5a For CN; where R a Selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl or 5-6 membered heterocyclic group.

41. A compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, wherein the compound is selected from Table 1 or Table 2.

42. A pharmaceutical composition comprising a compound according to any one of claims 1 to 41, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle, optionally with another therapeutic agent.

43. The pharmaceutical composition of claim 42, wherein the additional therapeutic agent is selected from the following target drugs / cell activity modulators, including CDK4 / 6 inhibitors, MAT2A inhibitors, MAPK1 / MAPK3 inhibitors, Type I PRMT inhibitors, EGFR inhibitors, SHP2 inhibitors, pan-KRAS inhibitors, KRASG12C inhibitors, RAF inhibitors, MEK inhibitors, ERK inhibitors, Bcl-2 inhibitors, SOS1 inhibitors, PARP inhibitors, MALT1 inhibitors, MALT2 inhibitors, BTK inhibitors, PI3K inhibitors, AKT inhibitors, FGFR inhibitors, DNA methyltransferase (DNMT) inhibitors, EZH1 / 2 inhibitors, EZH2 inhibitors, Menin-MLL inhibitors, IDH1 inhibitors, IDH2 inhibitors, IDH1 / 2 inhibitors, chemotherapeutic drugs, radiotherapy, STING agonists or immune checkpoint inhibitors / modulators.

44. Use of a compound according to any one of claims 1 to 41, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, in the preparation of a medicament for treating or preventing a PRMT5-mediated disease.

45. A method for treating or preventing a PRMT5-mediated disease in a subject, comprising administering to the subject a compound of any one of claims 1-41, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, or a pharmaceutical composition of claim 42 or 43.

46. ​​A compound according to any one of claims 1 to 41, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof, or a pharmaceutical composition according to claim 42 or 43, for use in treating or preventing a PRMT5-mediated disease.

47. The use of claim 44 or the method of claim 45 or the use of a compound or pharmaceutical composition of claim 46, wherein the disease is cancer.

48. The use of claim 44 or the method of claim 45 or the use of the compound or pharmaceutical composition of claim 46, wherein the PRMT5-mediated disease is selected from the group consisting of cancers: cardiac: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyomas, fibromas, lipomas, and teratomas; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, enchondroma, hamartoma, mesothelioma; Gastrointestinal tract: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, hemangioma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor), Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); genitourinary tract: kidney (adenocarcinoma, Weil's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma); Tumors (including Wilms' tumor, lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma), choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, lipoma); Liver: hepatocellular carcinoma, bile duct carcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gallbladder carcinoma, ampullary carcinoma, bile duct carcinoma; Bone: osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell chordoma, osteocartilaginous exostoses, benign enchondroma, chondroblastoma, fibrochondroma, osteoid osteoma, and giant cell tumor; Nervous system: skull (osteomas, hemangiomas, granulomas, xanthomas, and osteitis deformans); meninges (meningiomas, meningeal sarcomas, and gliomas); brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors (pinealomas), glioblastomas multiforme, oligodendrogliomas, schwannomas, retinoblastomas, and congenital tumors); spinal neurofibromas, meningiomas, gliomas, and sarcomas); gynecological: uterus (endometrial cancer (serous cystadenocarcinomas, mucinous cystadenocarcinomas, and unclassified carcinomas); granulosa cell tumors, Sertoli-Leydig cell tumors, dysgerminomas, and malignant teratomas); vulva (squamous cell carcinomas) , intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonic rhabdomyosarcoma), fallopian tube (carcinoma); hematology: blood (myeloid leukemias (acute and chronic), acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, nevus dysplasia, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and adrenal gland: neuroblastoma.

49. The use of claim 44 or the method of claim 45 or the compound or pharmaceutical composition of claim 46, wherein the PRMT5-mediated disease is selected from the group consisting of malignant peripheral nerve sheath tumor, mesothelioma, glioblastoma multiforme, pancreatic cancer, bile duct cancer, prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, bladder cancer, astrocytoma, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, thymoma, head and neck cancer, hepatocellular carcinoma, laryngeal cancer, squamous cell carcinoma of the lung, lung adenocarcinoma, oral cancer, ovarian cancer, kidney cancer and thyroid cancer, and sarcoma.

50. The use of claim 44 or the method of claim 45 or the use of the compound or pharmaceutical composition of claim 46, wherein the PRMT5-mediated disease is selected from MTAP-associated cancers, such as hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer or head and neck cancer.